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INTRODUCTION	  	  
	  
Juvenile	  dermatomyositis	  (JDM)	  is	  a	  multisystem	  vasculopathic	  disease	  of	  
presumably	  autoimmune	  etiology	  that	  primarily	  involves	  the	  skin	  and	  muscles,	  but	  
may	  affect	  many	  other	  systems,	  namely	  the	  gastrointestinal	  tract,	  heart	  and	  lungs.	  
It	   is	   also	   characterized	   by	   some	  peculiar	   and	   largely	  mysterious	   complications,	  
such	  as	  lipodistrophy	  and	  calcinosis.	  Although	  the	  prognosis	  of	  JDM	  has	  markedly	  
improved	   in	   the	   last	   three	   decades,	   there	   are	   still	   many	   patients	   who	   do	   not	  
respond	  to	  first-­‐line	  therapies	  and	  continue	  to	  have	  active	  disease.	  These	  patients	  
are	  at	  risk	  of	  developing	   irreversible	  damage	  from	  the	  disease	  or	   its	  treatment.	  
This	   damage	  may	   lead	   to	   permanent	   disability	   and	   affect	   the	   quality	   of	   life	   of	  
patients	  and	  their	  families.	   	  
Evaluation	  of	  disease	  activity	   is	  a	  fundamental	  component	  of	  the	  clinical	  
assessment	  of	  children	  with	  JDM,	  as	  persistently	  active	  disease	  plays	  a	  major	  role	  
in	  causing	  disease-­‐related	  damage	  and	  physical	  functional	  disability.	  Furthermore,	  
measurement	  of	  the	  level	  of	  disease	  activity	  over	  time	  is	  important	  in	  assessing	  
the	  effectiveness	  of	  therapeutic	  interventions	  in	  clinical	  trials	  and	  in	  monitoring	  
the	  patient’s	  course	  in	  daily	  care.	   	  
The	  optimal	  assessment	  of	  the	  level	  of	  disease	  activity	  in	  children	  with	  JDM	  
requires	  the	  availability	  of	  standardized	  tools.	  Standardization	  is	  fundamental	  to	  
ensure	  harmonization	  of	  assessments	  across	  different	  physicians	  and	  centers	  and	  
facilitate	   the	   comparability	   of	   results	   of	   therapeutic	   trials	   and	   other	   research	  
studies.	   Since	   JDM	   is	   a	   rare	   disease,	   research	   and	   clinical	   trials	   must	   involve	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multicenter	  and	  international	  collaborations.	  Collaborative	  efforts	  of	  international	  
experts	  are	  the	  best	  way	  to	  devise	  and	  validate	  standardized	  assessment	  tools	  and	  
to	  foster	  their	  widespread	  use.	  
Many	  tools	  are	  currently	  available	  for	  the	  assessment	  of	  disease	  activity	  in	  
JDM.	  However,	  most	  of	   the	  existing	  measures	  are	   lengthy,	   complex	  and	   fail	   to	  
adequately	   distinguish	   disease	   activity	   from	   damage.	   Therefore,	   they	   remain	  
essentially	  research	  tools	  and	  are	  rarely	  used	  in	  routine	  clinical	  practice.	  Another	  
problem	  with	  most	  of	  these	  measures	  is	  that	  they	  address	  only	  a	  single	  disease	  
domain	   and	   do	   not	   provide	   an	   overview	   of	   the	   overall	   disease	   impact.	   There	  
remains,	  therefore,	  the	  need	  for	  a	  concise	  and	  easily	  administered	  score	  tool	  that	  
is	  appropriate	  for	  use	  in	  clinical	  research,	  therapeutic	  trials,	  and	  routine	  care.	   	  
So	  far,	  no	  widely	  accepted	  definitions	  of	  JDM	  disease	  status	  (i.e.	  clinically	  
inactive	  disease,	  minimal	  disease	  activity,	  moderate	  disease	  activity,	  high	  disease	  
activity)	   are	  available.	   These	  definitions	  may	   represent	  useful	   treatment	   target	  
states	   for	   both	   physicians	   and	   parents/patients	   and	   could	   be	   included	   as	   an	  
outcome	  measure	   in	   future	   observational	   studies	   and	   clinical	   trials	   in	   JDM.	   A	  
composite	  disease	  activity	  score,	  which	  is	  made	  up	  by	  pooling	  multiple	  individual	  
measures	  of	  disease	  activity	  and	  provides	  a	   summary	  number	  on	  a	   continuous	  
scale,	   is	   ideally	   suitable	   to	   measure	   the	   overall	   level	   of	   disease	   activity	   in	   a	  
multisystem	  disease	  such	  as	  JDM	  and	  to	  establish	  the	  score	  thresholds	  (or	  cutoffs)	  
that	  correspond	  to	  the	  various	  disease	  activity	  states.	  	  
The	  research	  project	  that	  is	  subject	  of	  this	  work	  is	  aimed	  at	  developing	  a	  
composite	   disease	   activity	   score	   for	   JDM,	   named	   Juvenile	   DermatoMyositis	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Activity	  Index	  (JDMAI),	  and	  at	  providing	  preliminary	  evidence	  of	  its	  validity.	  	  
In	  the	  first	  part	  of	  the	  work,	  the	  development	  and	  composition	  of	  the	  six	  
preliminary	  versions	  of	  the	  JDMAI	  is	  described.	  In	  the	  second	  part,	  the	  new	  tool	  is	  
preliminarily	  validated	  using	  three	  large	  multinational	  patient	  samples.	  In	  the	  final	  
part	  of	  the	  project	  the	  validity	  of	  the	  JDMAI	  is	  prospectively	  tested	  in	  a	  sample	  of	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FIRST	  PART:	  DEVELOPMENT	  OF	  THE	  JUVENILE	  





Juvenile	  dermatomyositis	  (JDM)	  is	  a	  multisystem	  inflammatory	  disease	  of	  
unknown	  etiology	  that	  primarily	  involves	  the	  skin	  and	  skeletal	  muscles,	  but	  may	  
also	  affect	   visceral	  organs,	  particularly	   the	  gastrointestinal	   tract	  and	   lung	   [1,2].	  
Evaluation	   of	   disease	   activity	   is	   a	   fundamental	   component	   of	   the	   clinical	  
assessment	  of	  children	  with	  JDM,	  as	  persistently	  active	  disease	  plays	  a	  major	  role	  
in	  causing	  organ	  damage	  and	  functional	  disability.	  	  
In	   recent	   years,	   the	   treatment	   of	   JDM	   has	   been	   made	   more	   rational	  
through	   the	   scrutiny	   of	   novel	   and	   traditional	   medications	   in	   randomized	  
controlled	  trials	   [3,	  4]	  and	  the	  publication	  of	  consensus-­‐based	  expert	  advice	  on	  
optimal	  management	  [5-­‐10].	  To	  substantiate	  these	  advances,	  there	  is	  the	  need	  for	  
sensitive,	  precise,	  and	  feasible	  measures	  of	  disease	  activity.	  
A	  variety	  of	  instruments	  are	  available	  for	  measuring	  disease	  activity	  in	  JDM	  
[11,	   12],	   including	   global	   assessment	   scales,	   tools	   for	   quantification	   of	  muscle	  
strength	   and	   skin	   manifestations,	   functional	   ability	   and	   quality	   of	   life	  
questionnaires,	   muscle	   magnetic	   resonance	   imaging,	   electromyography,	  
capillaroscopy,	  muscle	  histopathology,	  and	  serum	  muscle	  enzymes.	  However,	  due	  
to	  the	  high	  variability	  in	  clinical	  presentation	  and	  course	  of	  JDM,	  no	  single	  measure	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can	  reliably	  capture	  disease	  activity	   in	  all	  patients.	  Conversely,	  evaluation	  of	  all	  
measures	   individually	   may	   raise	   methodological	   and	   statistical	   problems,	  
especially	  when	  they	  are	  employed	  as	  end	  points	  in	  clinical	  trials.	  	  
To	   enhance	   standardization,	   core	   sets	   of	   variables	   for	   assessment	   of	  
disease	  activity	  and	  therapeutic	  response	  in	  JDM	  have	  been	  established	  in	  parallel	  
by	  the	  Pediatric	  Rheumatology	  International	  Trials	  Organization	  (PRINTO)	  [13]	  and	  
the	  International	  Myositis	  Assessment	  and	  Clinical	  Studies	  Group	  (IMACS)	  [14-­‐19].	  
However,	  these	  tools	  are	  primarily	  proposed	  for	  use	  in	  research	  and	  clinical	  trials,	  
and	  are	  seldom	  applied	  in	  routine	  clinical	  care.	  
An	  alternative,	  pragmatic	  approach	  to	  the	  measurement	  of	  disease	  activity	  
in	  JDM	  can	  be	  modeled	  on	  the	  so-­‐called	  composite	  disease	  activity	  scores.	  These	  
tools	  are	  made	  up	  by	  pooling	  individual	  measures	  of	  disease	  activity	  into	  a	  single	  
instrument	   and	   aim	   to	   quantify	   the	   absolute	   level	   of	   activity	   by	   providing	   one	  
summary	  number	  on	  a	  continuous	  scale.	  They	  are	  thought	  to	  enhance	  consistency	  
in	  disease	  activity	  evaluation	  across	  physicians	  and	  may	  allow	  patients	  to	  better	  
understand	  the	  meaning	  of	  disease	  activity	  by	  providing	  a	  single	  score	  number.	  
Composite	  scores	  have	  been	  successfully	  introduced	  in	  juvenile	  idiopathic	  arthritis	  
(JIA)	  [20-­‐22].	  
At	  present,	  such	  measures	  do	  not	  exist	  for	  JDM.	  For	  this	  reason,	  the	  aim	  of	  
the	   present	   study	  was	   to	   develop	   a	   composite	   disease	   activity	   score	   for	   JDM,	  
called	   the	   Juvenile	   DermatoMyositis	   Activity	   Index	   (JDMAI),	   and	   to	   provide	  
preliminary	  evidence	  of	  its	  validity.	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Development	  of	  the	  JDMAI	  	  	  
	  
The	  JDMAI	  was	  devised	  by	  a	  group	  of	  eight	  paediatric	  rheumatologists	  with	  
2	  to	  >	  30	  years	  of	  experience	   in	   the	  assessment	  and	  care	  of	  children	  with	   JDM	  
(S.R.,	  A.C.,	  P.V.D.,	  G.C.V.,	  K.N.,	  C.P.,	  N.R.	  and	  A.R.),	  who	  reached	  consensus	  on	  the	  
individual	  measures	  to	  be	  included	  in	  the	  score.	  Investigators	  were	  asked	  to	  base	  
their	  choice	  on	  their	  clinical	  experience	  and	  on	  a	  review	  of	  the	  pertinent	  literature.	  
After	   extensive	   discussion	   on	   which	   items	   should	   be	   included	   in	   the	   tool,	  
agreement	   among	   investigators	   was	   reached	   on	   the	   following	   four	   clinical	  
domains:	   physician’s	   global	   assessment	   of	   overall	   disease	   activity	   (PhGA)	   on	   a	  
visual	  analogue	  scale	   (VAS)	   (where	  0	  =	  no	  activity	  and	  10	  =	  maximum	  activity);	  
parent’s/patient’s	   global	   assessment	  of	   patient’s	   overall	  wellbeing	   (PaGA)	  on	   a	  
VAS	   (where	   0	   =	   best	   and	   10	   =	   worst);	   assessment	   of	   muscle	   strength;	   and	  
assessment	  of	  skin	  disease	  activity.	  	  
Because	   no	   universally	   embraced	   scales	   for	   measurement	   of	   muscle	  
strength	  and	  skin	  disease	  activity	  in	  JDM	  exist,	  it	  was	  decided	  to	  test	  various	  JDMAI	  
versions	   that	   included	   different	   instruments	   for	   the	   assessment	   of	   these	   two	  
constructs.	   For	   muscle	   strength,	   the	   selected	   tools	   were	   the	   Manual	   Muscle	  
Testing	  8	  (MMT8)	  (score	  range	  0	  =	  worst	  to	  80	  =	  best)	  [23],	  the	  Childhood	  Myositis	  
Assessment	  Scale	  (CMAS)	  (score	  range	  0	  =	  worst	  to	  52	  =	  best)	  [24,	  25],	  and	  the	  
hybrid	  MMT8/CMAS	  (hMC)	  (score	  range	  0	  =	  worst	  to	  100	  =	  best)	  [26].	  To	  estimate	  
the	  activity	  of	  skin	  disease,	  the	  physician’s	  global	  assessment	  of	  the	  activity	  of	  skin	  
disease	   on	   a	   10-­‐cm	  VAS	   (skin	   activity	   VAS,	   score	   range	   0	   =	   no	   activity	   to	   10	   =	  
maximum	  activity)	  and	   the	   skin	   component	  of	   the	  Disease	  Activity	  Score	   (DAS)	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(DAS	  skin,	  score	  range	  0	  =	  no	  activity	  to	  9	  =	  maximum	  activity)	  [27]	  were	  chosen.	  	  
In	  constructing	  the	  JDMAI,	  we	  realized	  that	  the	  score	  range	  of	  the	  three	  
muscle	  strength	  tools	  was	  much	  wider	  than	  that	  of	  the	  other	  items.	  Furthermore,	  
we	   noticed	   in	   the	   study	   patients	   that	   their	   scores	   were	   skewed	   towards	   the	  
normal	   end	   of	   the	   scale.	   We	   therefore	   decided,	   in	   order	   to	   improve	   score	  
distribution	  and	  avoid	  giving	  the	  muscle	  strength	  tools	  an	  excessive	  weight	  in	  the	  
index,	   to	  express	  muscle	  scores	   in	  deciles.	  Decile	  calculation	  was	  performed	  by	  
pooling	  the	  scores	  of	  all	  patients	  included	  in	  the	  study	  datasets	  (n	  =	  627).	  Thus,	  
the	  score	  range	  of	  all	  three	  muscle	  strength	  tools	  ranges	  from	  0	  to	  10.	  For	  sake	  of	  
consistency,	  scores	  were	  reversed	  to	  give	  them	  the	  same	  direction	  (i.e.	  0	  =	  best	  to	  
10	  =	  worst)	  as	  the	  other	  JDMAI	  components.	  The	  minimum	  cutoffs	  (MMT8	  <	  22;	  
CMAS	  <	  6;	  hMC	  <	  23)	  correspond	  to	  the	  maximum	  muscle	  score	  values	  of	  patients	  
in	  the	  weakest	  decile	  (i.e.	  decile	  score	  =	  10).	  The	  rule	  of	  score	  conversion	  in	  deciles	  
is	  shown	  in	  Table	  1.	  The	  six	  versions	  of	  the	  JDMAI	  tested	  in	  validation	  analyses	  and	  
their	  theoretical	  range	  are	  presented	  in	  Table	  2.	  	  
	  
Table	   1.	   Rule	   of	   conversion	   of	   the	   scores	   of	  muscle	   strength	   tools	   into	   decile	  
scores.	  	  
MMT8	   CMAS	   hMC	   Decile	  score	  
<	  22	   <	  6	   <	  23	   10	  
≥	  22	  to	  <	  33	   ≥	  6	  to	  <	  12	   ≥	  23	  to	  <	  34	   	  	  9	  
≥	  33	  to	  <	  40	   ≥	  12	  to	  <	  19	   ≥	  34	  to	  <	  42	   	  	  8	  
≥	  40	  to	  <	  48	   ≥	  19	  to	  <	  22	   ≥	  42	  to	  <	  50	   	  	  7	  
≥	  48	  to	  <	  52	   ≥	  22	  to	  <	  28	   ≥	  	  50	  to	  <	  58	   	  	  6	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≥	  52	  to	  <	  58	   ≥	  28	  to	  <	  32	   ≥58	  to	  <	  64	   	  	  5	  
≥	  58	  to	  <	  63	   ≥	  32	  to	  <	  37	   ≥	  64	  to	  <	  72	   	  	  4	  
≥	  63	  to	  <	  70	   ≥	  37	  to	  <	  43	   ≥	  72	  to	  <	  81	   	  	  3	  
≥	  70	  to	  <	  77	   ≥	  43	  to	  <	  48	   ≥	  81	  to	  <	  93	   	  	  2	  
≥	  77	  to	  <	  80	   ≥	  48	  to	  <	  52	   ≥	  93	  to	  <	  100	   	  	  1	  
80	   52	   100	   	  	  0	  
	  
	  
Table	   2.	   Composition	   and	   theoretical	   range	   of	   the	   composite	   disease	   activity	  
scores	  tested	  in	  the	  study.	  	  
	  
JDMAI1	   JDMAI2	   JDMAI3	   JDMAI4	   JDMAI5	   JDMAI6	  
Physician’s	  global	  assessment	  of	  overall	  disease	  activity	  (0-­‐10)	  
Parent’s/patient’s	  global	  assessment	  of	  overall	  well-­‐being	  (0-­‐10)	  














0-­‐40	   0-­‐39	   0-­‐40	   0-­‐39	   0-­‐40	   0-­‐39	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SECOND	  PART:	  PRELIMINARY	  VALIDATION	  OF	  THE	  




Three	   multinational	   samples	   composed	   of	   patients	   with	   probable	   or	  
definite	  JDM	  by	  Bohan	  and	  Peter	  criteria	  [28,	  29]	  were	  used	  to	  validate	  the	  JDMAI.	  
The	   first	  was	   an	   inception	   cohort	   of	   275	  patients	   enrolled	   in	   a	   study	   aimed	   to	  
validate	   prospectively	   the	   “Provisional	   PRINTO/American	   College	   of	  
Rheumatology/European	   League	  Against	   Rheumatism	  Disease	  Activity	   Core	   Set	  
for	  the	  Evaluation	  of	  Response	  to	  Therapy	  in	  Juvenile	  Dermatomyositis”	  [17].	  All	  
patients	  had	  active	  disease	  at	  study	  entry	  and	  were	  assessed	  at	  baseline	  and	  6	  
months	  after	  a	  major	  therapeutic	  intervention.	  The	  second	  sample	  included	  139	  
patients	  enrolled	  in	  a	  randomized	  controlled	  trial	  aimed	  to	  compare	  the	  efficacy	  
and	  safety	  of	  prednisone	  alone	  with	  that	  of	  prednisone	  plus	  either	  methotrexate	  
or	  ciclosporin	  [4].	  The	  third	  sample	  comprised	  213	  patients	  followed	  in	  standard	  
clinical	   care	   at	   13	   international	   pediatric	   rheumatology	   centers	   and	   evaluated	  
prospectively	  at	  baseline	  and	  after	  a	  median	  of	  5.9	  months.	  For	  sake	  of	  brevity,	  
the	  three	  datasets	  will	  hereafter	  be	  named	  PRINTO	  sample,	  JDM	  trial	  sample,	  and	  
Routine	  sample,	  respectively.	  The	  proportion	  of	  patients	  who	  had	  definite	  JDM	  by	  
the	   2017	   European	   League	   Against	   Rheumatism/American	   College	   of	  
Rheumatology	   classification	   criteria	   [30]	  was	   97.1%	   in	   the	   PRINTO	   sample	   and	  
98.6%	  in	  the	  JDM	  trial	  sample.	  These	  criteria	  could	  not	  be	  applied	  in	  the	  Routine	  
sample	  due	   to	   the	   lack	  of	   sufficiently	  detailed	   information	  at	  disease	  onset	   for	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most	  patients.	  
Clinical	   assessment	   in	   all	   patients	   comprised	   muscle	   strength	  
measurement	  with	  MMT8,	  CMAS	  and	  hMC	  as	  well	  as	  quantification	  of	  the	  other	  
aspects	   of	   disease	   impact	   through	   the	   traditional	   physician-­‐centred	   or	   parent-­‐
reported	  outcome	  measures	  for	  JDM.	  These	  measures	  included,	  depending	  on	  the	  
sample,	  the	  PhGA,	  PaGA,	  parent’s	  assessment	  of	  the	  intensity	  of	  pain	  on	  a	  10-­‐cm	  
VAS	  (0	  =	  no	  pain;	  10	  =	  maximum	  pain),	  parent’s	  assessment	  of	  fatigue	  on	  a	  10-­‐cm	  
VAS	  (0	  =	  no	  fatigue;	  10	  =	  maximum	  fatigue),	  calculation	  of	  overall	  disease	  activity	  
through	   the	   total	   score	   of	   the	   DAS	   (DAS	   total,	   0	   =	   no	   activity;	   20	   =	  maximum	  
activity)	  [27],	  assessment	  of	  muscle	  disease	  activity	  with	  the	  muscle	  component	  
of	  the	  DAS	  (DAS	  muscle,	  0	  =	  no	  activity;	  11	  =	  maximum	  activity)	  [27]	  or	  physician’s	  
global	  assessment	  of	  muscle	  disease	  activity	  on	  a	  10-­‐cm	  VAS	  (muscle	  activity	  VAS,	  
0	   =	   no	   activity;	   10	   =	   maximum	   activity)	   [31],	   and	   the	   assessment	   of	   physical	  
function	   through	   the	   Childhood	  Health	   Assessment	  Questionnaire	   (CHAQ)	   (0	   =	  
best;	  3	  =	  worst)	  [32].	  Health-­‐related	  quality	  of	  life	  (HRQL)	  was	  assessed	  through	  
the	   Child	   Health	   Questionnaire	   (CHQ),	   and	   expressed	   by	   the	   CHQ	   physical	  
summary	  score	  (CHQ-­‐PhS)	  and	  CHQ	  psychosocial	  summary	  score	  (CHQ-­‐PsS)	  [33,	  
34].	  Cumulative	  damage	  was	  assessed	  with	  the	  Myositis	  Damage	  Index	  (MDI)	  (0	  =	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Validation	  procedures	  
	  
Validation	  of	  the	  JDMAI	  was	  conducted	  following	  the	  Outcome	  Measures	  
in	  Rheumatoid	  Arthritis	  Clinical	  Trials	  (OMERACT)	  filter	  for	  outcome	  measures	  in	  
rheumatology	   [35,	  36].	   Feasibility	  or	  practicality	  was	  determined	  by	  addressing	  
the	   issues	  of	  brevity,	  simplicity	  and	  easy	  scoring	  [37].	  Face	  and	  content	  validity	  
were	  obtained	  as	  stated	  above.	  	  
Construct	  validity	  was	  assessed	  by	  calculating	  the	  correlations	  of	  the	  JDMAI	  
with	  the	  outcome	  measures	  not	  included	  in	  the	  tool.	  Given	  that	  the	  JDMAI	  was	  
devised	  to	  measure	  JDM	  disease	  activity	  and	  incorporates	  both	  muscle	  and	  skin	  
components,	   it	  was	  predicted	  that	   its	  correlation	  with	  muscle	  activity	  VAS,	  DAS	  
total,	   DAS	  muscle,	  MMT8,	   CMAS,	   hMC,	   skin	   activity	   VAS	   and	   DAS	   skin,	   which	  
assess	  related	  constructs,	  would	  be	  moderate-­‐to-­‐high.	  Correlations	  with	  CK,	  pain	  
VAS,	   fatigue	   VAS,	   CHAQ	   score,	   CHQ-­‐PhS	   and	   CHQ-­‐PsS	   were	   predicted	   to	   be	  
moderate-­‐to-­‐low,	  as	  these	  measures	  combine	  the	  effect	  of	  disease	  activity	  with	  
that	   of	   other	   constructs,	   including	   external	   factors	   unrelated	   to	   the	   disease.	  
Correlations	  with	  MDI	  were	  predicted	  to	  be	  low	  as	  this	  tool	  measures	  a	  different	  
construct.	   In	   JDM	   trial	   and	   Routine	   datasets,	   correlations	   were	   assessed	   at	  
baseline	  visit.	  Correlations	  were	  computed	  using	  Spearman’s	  rank	  statistics	  and	  
were	  considered	  high	  if	  >	  0.7,	  moderate	  if	  0.4-­‐0.7	  and	  low	  if	  <	  0.4	  [38,	  39].	  
Internal	  consistency	  was	  assessed	  using	  Cronbach’s	  alpha	  coefficient	  [40]	  
and	  was	  defined	  as	  follows:	  <	  0.6	  =	  poor,	  0.6-­‐0.64	  =	  slight,	  0.65-­‐0.69	  =	  fair,	  0.7-­‐
0.79	   =	  moderate,	   0.8-­‐0.89	   =	   substantial,	   and	   >	   0.9	   =	   almost	   perfect	   [41].	   The	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internal	   structure	  of	   the	   JDMAI	  was	  examined	  using	  exploratory	   factor	  analysis	  
[42],	   which	   can	   determine	   if	   a	   scale	   is	  measuring	  more	   than	   one	   construct.	   It	  
generates	  factor	  loadings,	  which	  are	  measurements	  of	  how	  strongly	  the	  observed	  
variables	  in	  the	  scale	  are	  associated	  with	  its	  latent	  factor(s).	  
To	  evaluate	  whether	  the	  JDMAI	  can	  differentiate	  between	  patients	  with	  
varying	   levels	   of	   disease	   activity,	   we	   compared	   its	   scores	   between	   patients	  
grouped	  using	  physicians’	  subjective	  estimation	  of	  current	  disease	  activity	  (rated	  
as	   inactive	   disease	   or	   low,	   moderate	   or	   high	   disease	   activity),	   and	   parents’	  
satisfaction	  with	  illness	  outcome.	  To	  evaluate	  satisfaction,	  parents	  were	  asked	  the	  
question,	   ‘Considering	  all	   the	  ways	   the	   illness	   affects	   your	   child,	  would	   you	  be	  
satisfied	   if	   his/her	   condition	   remained	   stable/unchanged	   for	   the	   next	   few	  
months?’,	  which	  was	   to	   be	   answered	   yes	   or	   no	   [43].	   It	  was	   expected	   that	   the	  
JDMAI	  score	  was	  lower	  among	  patients	  judged	  by	  the	  physician	  as	  being	  in	  a	  state	  
of	   inactive	   disease	   or	   whose	   parents	   were	   satisfied	   with	   illness	   outcome.	  
Comparison	   among	   groups	   was	   made	   by	   the	   Mann-­‐Whitney	   U	   test	   and	   the	  
Kruskall-­‐Wallis	  test,	  as	  appropriate.	  
Responsiveness	  of	  JDMAI	  to	  change	  between	  two	  consecutive	  visits	  was	  
assessed	  by	  computing	  the	  standardized	  response	  mean	  (SRM),	  calculated	  as	  the	  
mean	  change	  in	  score	  divided	  by	  the	  S.D.	  of	  individuals’	  change	  in	  score.	  According	  
to	  Cohen	  [44],	  threshold	  levels	  for	  SRM	  were	  defined	  as	  follows:	  ≥	  0.2	  =	  small,	  ≥	  
0.5	  =	  moderate,	  and	  ≥	  0.80	  =	  good.	  	  
All	   statistical	   tests	   were	   two	   sided;	   a	   P	   value	   <	   0.05	   was	   considered	  
statistically	  significant.	  The	  statistical	  packages	  used	  were	  ‘Statistica’	  (release	  6.1,	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StatSoft,	  Tulsa,	  OK,	  USA),	  Stata	  release	  9.2	  (Stata	  Corporation,	  College	  Station,	  TX,	  
USA),	  XLSTAT	  (version	  1.02,	  Addinsoft,	  2013),	  and	  R	  statistics	  (version	  3.3.3)	  [The	  





The	  main	  demographic	  and	  clinical	  features	  of	  the	  three	  patient	  datasets	  
are	  shown	   in	  Table	  3.	  The	  gender	   ratio	  and	  average	  age	  at	  disease	  onset	  were	  
comparable	  across	  datasets,	  although	  patients	  in	  the	  Routine	  sample	  had	  a	  slightly	  
younger	  disease	  presentation.	  On	  average,	  patients	  in	  all	  three	  datasets	  had	  short	  
disease	  duration.	  As	  expected,	  patients	  in	  PRINTO	  and	  JDM	  trial	  samples,	  which	  
comprised	  patients	  with	  active	  disease,	  had	  a	  higher	  level	  of	  disease	  activity	  than	  
patients	  in	  the	  Routine	  sample,	  which	  included	  patients	  followed	  in	  routine	  clinical	  
care.	  Patients	  who	  had	  health-­‐related	  quality	  of	   life	  assessment	  available	  had	  a	  
greater	  impairment	  in	  physical	  than	  in	  psychosocial	  well-­‐being.	  The	  low	  MDI	  score	  
reflects	  the	  average	  short	  disease	  duration	  of	  patients	  enrolled.	  The	  score	  values	  
of	  the	  six	  versions	  of	  the	  JDMAI	  in	  the	  three	  patient	  samples	  are	  provided	  in	  Table	  
4.	  
	  
Table	   3.	   Demographic	   features	   and	   values	   of	   outcome	  measures	   of	   the	   three	  
patient	  samples.	  	  
	  






N	  =	  275	  	  	  
JDM	  trial	  
sample	  
N	  =	  139	  
Routine	  
sample	  
N	  =	  213	  
	   Min	  –	  Max	   Median	  (IQR)	   Median	  (IQR)	   Median	  (IQR)	  
Sex	  (Female)	   -­‐	   168	  (61.1%)	   82	  (59.0%)	   132	  (62.0%)	  
Age	  at	  disease	  onset	   -­‐	   7.3	  (4.2	  -­‐	  10.2)	   7.4	  (4.5	  -­‐	  10.6)	   6.2	  (4.0-­‐9.1)	  	  	  
Age	  at	  1st	  visit	  (years)	   -­‐	   8.7	  (5.9	  -­‐	  12.7)	   7.6	  (4.7	  -­‐	  10.8)	   8.4	  (5.0-­‐12.3)	  
Disease	  duration	  
(years)	  
-­‐	   0.6	  (0.2	  -­‐	  2.1)	   0.2	  (0.1	  -­‐	  0.4)	   0.5	  (0.2-­‐1.9)	  
PhGA	   0-­‐10	   5.5	  (3.4	  -­‐	  7.2)	  	   6.4	  (5.0	  –	  8.0)	   4.0	  (1.0-­‐7.0)	  
Muscle	  activity	  VAS	   0-­‐10	   5.2	  (2.9	  –	  7.4)	   6.3	  (5.0	  –	  8.0)	   1.5	  (0.0-­‐4.0)	  
Skin	  activity	  VAS	   0-­‐10	   5.0	  (2.3	  –	  6.7)	   5.0	  (3.0	  –	  7.0)	   2.0	  (0.0-­‐5.0)	  
DAS	   0-­‐20	   12	  (10-­‐15)	   13	  (11	  -­‐	  15)	   6	  (2-­‐13)	  
DAS	  -­‐	  muscle	  	   0-­‐11	   6	  (4	  –	  8)	   7	  (6	  –	  9)	   2.5	  (0-­‐7)	  
DAS	  -­‐	  skin	  	   0-­‐9	   6	  (5	  –	  7)	   6	  (5	  –	  7)	   4	  (1-­‐7)	  
MMT8	  	   0-­‐80	   48	  (32	  -­‐	  62)	   46	  (34-­‐57)	   74	  (61-­‐79)	  
CMAS	   0-­‐52	   27	  (13	  -­‐	  36)	   20	  (13	  -­‐	  33)	   47.0	  (34.0-­‐
52.0)	  
hMC	   0-­‐100	   52	  (35	  -­‐	  71)	   49	  (34	  -­‐	  63)	   89.6	  (68.1-­‐
97.6)	  
Creatine	  kinase,	  U/L	   0	  –	  150*	   251	  (70-­‐1395)	   741	  (155	  –	  
2978)	  
103	  (50-­‐	  688)	  
MDI	  	  	   0-­‐35	   0.0	  (0.0	  –	  4.0)	   0.0	  (0.0	  –	  1.1)	   NA	  
PaGA	   0-­‐10	   5.2	  (3.0	  –	  7.4)	   5.8	  (4.4	  -­‐	  7.0)	   1.7	  (0.0-­‐5.0)	  
Pain	  VAS	   0-­‐10	   3.2	  (0.8	  –	  6.0)	   5.0	  (3.0	  –	  7.0)	  	   1	  (0.0-­‐9.5)	  
Fatigue	  VAS	  	   0-­‐10	   NA	   NA	   2	  (0-­‐8)	  
CHAQ	   0-­‐3	   1.6	  (1.0	  –	  2.5)	   1.8	  (1.3	  -­‐	  2.5)	   1.5	  (1.0-­‐2.2)	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CHQ-­‐PhS	  	   40-­‐60	   32.0	  (23.5	  –	  
42.5)	  	  
15.6	  (8.0	  -­‐	  24.4)	  	   NA	  
CHQ-­‐PsS	   40-­‐60	   45.9	  (40.2	  –	  
52.2)	  	  
40.0	  (29.7	  -­‐	  
48.0)	  
NA.	  
IQR	  =	  Interquartile	  Range;	  NA	  =	  Not	  Available.	  	  
	  
Table	  4.	  Scores	  of	  the	  six	  versions	  of	  the	  JDMAI	  in	  the	  three	  patient	  samples.	  
	  








	   Min	  –	  Max	   Median	  (IQR)	   Median	  (IQR)	   Median	  (IQR)	  
JDMAI1	   0-­‐40	   22	  (15.9	  -­‐	  27.1)	  	  	   23.3	  (19.3	  -­‐	  27.9)	  	  	   6.8	  (1	  -­‐	  17.5)	  	  	  
JDMAI2	   0-­‐39	   22.2	  (17.3	  -­‐	  27.7)	  	  	   25	  (20.1	  -­‐	  28)	  	   8.3	  (2	  -­‐	  16)	  	  	  
JDMAI3	   0-­‐40	   22.1	  (15.9	  -­‐	  27.4)	  	  	   23.8	  (19	  -­‐	  28)	   7.5	  (1.5	  -­‐	  17.5)	  	  	  
JDMAI4	   0-­‐39	   22.2	  (17.2	  -­‐	  28.3)	  	  	   24.1	  (20.3	  -­‐	  28)	  	  	   8.8	  (2	  -­‐	  16)	  	  	  
JDMAI5	   0-­‐40	   21.4	  (15.8	  -­‐	  27)	  	  	   23.9	  (19	  -­‐	  27.8)	   6.5	  (1	  -­‐	  18)	  	  	  
JDMAI6	   0-­‐39	   21.3	  (17.3	  -­‐	  28)	  	  	   24.5	  (20	  -­‐	  28.6)	   8.5	  (2	  -­‐	  17)	  	  	  
	  IQR	  =	  Interquartile	  Range.	  	  
	  
Construct	  validity.	  The	  Spearman’s	  correlations	  between	  the	  six	  versions	  
of	  the	  JDMAI	  and	  the	  JDM	  clinical	  measures	  not	  included	  in	  the	  score	  are	  shown	  
in	  Table	  5.	  In	  the	  PRINTO	  sample,	  correlations	  for	  JDMAI	  were	  high	  with	  muscle	  
activity	  VAS,	  DAS	  total	  and	  CHAQ,	  moderate-­‐to-­‐high	  with	  MMT8,	  CMAS	  and	  hMC,	  
moderate	  with	  skin	  activity	  VAS,	  DAS	  muscle,	  DAS	  skin,	  pain	  VAS	  and	  CHQ-­‐PhS,	  
and	  low	  with	  CK,	  MDI,	  and	  CHQ-­‐PsS.	   In	  the	  JDM	  trial	  sample,	  correlations	  were	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moderate-­‐to-­‐high	  with	  DAS	  total,	  MMT8,	  and	  hMC,	  moderate	  with	  muscle	  activity	  
VAS,	  DAS	  muscle,	  CMAS,	  pain	  VAS,	  and	  CHAQ,	  low-­‐to-­‐moderate	  with	  skin	  activity	  
VAS,	  DAS	  skin,	  CHQ-­‐PhS,	  and	  CHQ-­‐PsS,	  and	  low	  with	  CK	  and	  MDI.	  In	  the	  Routine	  
sample,	   correlations	  were	  high	  with	  muscle	  activity	  VAS,	   skin	  activity	  VAS,	  DAS	  
total,	  DAS	  muscle,	  DAS	  skin,	  MMT8,	  CMAS	  and	  hMC	  and	  moderate	  with	  CK,	  pain	  
VAS	  and	  fatigue	  VAS.	  Correlations	  were	  overall	  in	  line	  with	  prediction,	  but	  were	  
higher	  for	  the	  Routine	  sample	  than	  for	  the	  other	  two	  datasets.	  
	  
Table	  5.	  Spearman’s	  Rank	  correlation	  between	  the	  six	  versions	  of	  the	  JDMAI	  and	  
JDM	  outcome	  measures.	  
	  
	   JDMAI1	   JDMAI2	   JDMAI3	   JDMAI4	   JDMAI5	   JDMAI6	  
PRINTO	  sample	   	   	   	   	   	   	  
	  	  	  Muscle	  activity	  VAS	   0.75	  	  	   0.76	  	  	   0.74	  	  	   0.75	  	  	   0.77	  	  	   0.78	  	  	  
	  	  	  Skin	  activity	  VAS	   -­‐	   0.45	  	  	   -­‐	   0.46	  	  	   -­‐	   0.42	  
	  	  	  DAS	  total	   0.72	  	  	   0.77	  	  	   0.71	  	   0.77	   0.72	  	   0.77	  	  
	  	  	  DAS	  muscle	   0.64	  	  	   0.68	  	  	   0.64	  	  	   0.68	  	  	   0.66	  	  	   0.69	  	  	  
	  	  	  DAS	  skin	   0.42	  	  	   -­‐	   0.43	  	  	   -­‐	   0.41	  	  	   -­‐	  
	  	  	  MMT8	   -­‐0.70	  	  	   -­‐0.74	  	  	   -­‐	   -­‐	   -­‐0.66	  	  	   -­‐0.69	  	  
	  	  	  CMAS	   -­‐0.69	  	  	   -­‐0.75	  	  	   -­‐0.68	  	  	   -­‐0.74	  	   -­‐	   -­‐	  
	  	  	  hMC	   -­‐	   -­‐	   -­‐0.71	  	  	   -­‐0.76	  	   -­‐0.68	  	  	   -­‐0.72	  	  	  
	  	  	  Creatine	  kinase	   0.26	  	  	   0.28	  	  	   0.26	  	  	   0.28	  	  	   0.28	  	   0.30	  	  	  
	  	  	  MDI	   0.23	  	  	   0.20	  	  	   0.23	  	  	   0.20	   0.21	  	  	   0.18	  	  	  
	  	  	  Pain	  VAS	   0.49	  	  	   0.52	  	   0.48	  	  	   0.51	  	   0.49	  	   0.52	  	  
	  	  	  CHAQ	  	  	   0.72	  	  	   0.77	  	  	   0.72	  	  	   0.77	  	  	   0.75	  	  	   0.79	  	  	  
	  	  	  CHQ	  Phs	  	   -­‐0.61	  	  	   -­‐0.65	  	  	   -­‐0.60	  	  	   -­‐0.64	  	  	   -­‐0.62	  	   -­‐0.66	  	  	  
	  	  	  CHQ	  PsS	   -­‐0.22	  	  	   -­‐0.22	  	  	   -­‐0.23	  	   -­‐0.23	  	  	   -­‐0.22	  	  	   -­‐0.21	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JDM	  trial	  sample	   	   	   	   	   	   	  
	  	  	  Muscle	  activity	  VAS	   0.65	  	  	   0.63	  	  	   0.62	  	  	   0.6	  	  	   0.66	   0.64	  
	  	  	  Skin	  activity	  VAS	   -­‐	   0.39	  	  	   -­‐	   0.42	  	  	   -­‐	   0.39	  
	  	  	  DAS	  total	   0.67	  	  	   0.71	  	  	   0.63	  	  	   0.67	  	  	   0.70	   0.74	  
	  	  	  DAS	  muscle	   0.56	  	  	   0.59	  	  	   0.51	  	   0.54	  	  	   0.62	   0.64	  
	  	  	  DAS	  skin	   0.35	  	  	   -­‐	   0.36	  	  	   -­‐	   0.34	   -­‐	  
	  	  	  MMT8	   -­‐0.69	  	  	   -­‐0.72	  	  	   -­‐	   -­‐	   -­‐0.62	  	  	   -­‐0.64	  	  	  
	  	  	  CMAS	   -­‐0.65	  	  	   -­‐0.68	  	  	   -­‐0.60	  	  	   -­‐0.63	  	  	   -­‐	   -­‐	  
	  	  	  hMC	   -­‐	   -­‐	   -­‐0.70	  	  	   -­‐0.74	  	  	   -­‐0.67	  	  	   -­‐0.71	  	  	  
	  	  	  Creatine	  kinase	   0.25	  	  	   0.25	  	  	   0.23	  	  	   0.24	  	  	   0.27	   0.27	  
	  	  	  MDI	   -­‐0.08	  	  	   -­‐0.11	  	  	   -­‐0.05	  	  	   -­‐0.08	  	  	   -­‐0.07	  	   -­‐0.09	  	  	  
	  	  	  Pain	  VAS	   0.45	  	  	   0.48	  	  	   0.44	  	  	   0.48	  	  	   0.47	  	  	   0.5	  	  	  
	  	  	  CHAQ	  	  	   0.48	  	  	   0.51	  	  	   0.46	  	  	   0.48	  	  	   0.51	   0.54	  
	  	  	  CHQ	  PhS	  	   -­‐0.39	  	  	   -­‐0.40	  	  	   -­‐0.37	  	  	   -­‐0.39	  	  	   -­‐0.42	  	  	   -­‐0.44	  	  	  
	  	  	  CHQ	  PsS	   -­‐0.33	  	  	   -­‐0.33	  	   -­‐0.32	  	  	   -­‐0.33	  	  	   -­‐0.36	  	  	   -­‐0.35	  	  	  
Routine	  sample	   	   	   	   	   	   	  
	  	  	  Muscle	  activity	  VAS	   0.87	   0.87	   0.88	  	  	   0.88	  	  	   0.87	  	  	   0.87	  	  
	  	  	  Skin	  activity	  VAS	   -­‐	   0.88	   -­‐	   0.86	   -­‐	   0.89	  
	  	  	  DAS	  total	   0.91	  	  	   0.95	  	  	   0.90	  	  	   0.95	  	  	   0.90	  	  	   0.95	  	  	  
	  	  	  DAS	  muscle	   0.79	  	  	   0.81	  	   0.76	  	  	   0.82	  	  	   0.8	  	  	   0.82	  	  
	  	  	  DAS	  skin	   0.75	  	  	   -­‐	   0.71	  	  	   -­‐	   0.73	  	  	   -­‐	  
	  	  	  MMT8	   -­‐0.82	  	  	   -­‐0.83	  	  	   -­‐	   -­‐	   -­‐0.79	  	  	   -­‐0.81	  	  	  
	  	  	  CMAS	   -­‐0.81	   -­‐0.8	   -­‐0.81	   -­‐0.8	   -­‐	   -­‐	  
	  	  	  hMC	   -­‐	   -­‐	   -­‐0.84	  	  	   -­‐0.84	  	  	   -­‐0.83	  	  	   -­‐0.83	  	  	  
	  	  	  Creatine	  kinase	   0.44	  	  	   0.42	  	  	   0.45	  	  	   0.41	  	  	   0.44	  	  	   0.42	  	  	  
	  	  	  Pain	  VAS	   0.65	  	  	   0.65	  	  	   0.65	  	  	   0.65	  	  	   0.64	  	  	   0.63	  	  	  
	  	  	  Fatigue	  VAS	   0.65	  	  	   0.65	  	  	   0.64	  	  	   0.63	  	  	   0.65	  	  	   0.64	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Internal	  consistency.	  Cronbach’s	  alpha	  values	  were	  fair-­‐to-­‐moderate	  in	  the	  
PRINTO	   sample,	   slight-­‐to-­‐poor	   in	   the	   JDM	   trial	   sample,	   and	   substantial	   in	   the	  
Routine	   sample	   (see	   Table	   6).	   That	   the	   internal	   consistency	   was	   lower	   in	   the	  
PRINTO	  and	  JDM	  trial	  samples	  than	  in	  the	  Routine	  dataset	  could	  depend	  on	  the	  
difference	   in	   the	   state	  of	   the	  disease,	  which	  was	   active,	   and,	   thus,	   likely	  more	  
variable,	  in	  all	  patients	  included	  in	  the	  former	  datasets	  and	  overall	  more	  stable	  in	  
patients	  followed	  in	  routine	  care.	  
	  
	  
Table	  6.	  Cronbach’s	  alpha	  value	  of	  internal	  consistency	  for	  the	  six	  JDMAI	  versions	  
in	  the	  three	  patient	  datasets.	  
	  
	   PRINTO	  sample	   JDM	  trial	  sample	   Routine	  sample	  
JDMAI1	   0.69	  	  	   0.62	  	  	   0.89	  	  	  
JDMAI2	   0.69	  	  	   0.59	  	  	   0.87	  	  	  
JDMAI3	   0.69	  	  	   0.62	  	  	   0.88	  	  	  
JDMAI4	   0.69	  	  	   0.58	  	  	   0.85	  	  	  
JDMAI5	   0.70	  	  	   0.62	  	  	   0.88	  	  
JDMAI6	   0.70	  	  	   0.58	  	   0.86	  	  
	  	  
	  
Exploratory	  factor	  analysis.	  Exploratory	  factor	  analysis	  of	  JDMAI	  led	  to	  the	  
unambiguous	   identification	   of	   two	   separate	   factors:	   one	   factor	   incorporated	  
muscle	  strength	  assessment,	  PhGA	  and	  PaGA;	  the	  second	  factor	  incorporated	  skin	  
assessment	  (Table	  7).	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Table	  7.	  Results	  of	  exploratory	  factor	  analysis	  in	  the	  JDM	  trial	  sample.	  	  
	  
	   N°	  of	  factors	  Correlation	  between	  factors	   Factors	   Components	  (loadings)	  
JDMAI1	   2	   0.3	  
1	  
hMC	  (0.8)	  	  
PhGA	  (0.5)	  	  
PaGA	  (0.5)	  	  
2	   Skin	  VAS	  (0.6)	  	  
JDMAI2	   2	   0.1	  
1	  
hMC	  (0.8)	  	  
PhGA	  (0.7)	  	  
PaGA	  (0.6)	  	  
2	   Skin	  DAS	  (0.4)	  	  
JDMAI3	   2	   0.4	  
1	  
MMT8	  (0.8)	  	  
PhGA	  (0.5)	  	  
PaGA	  (0.5)	  	  
2	   Skin	  VAS	  (0.6)	  	  
JDMAI4	   2	   0.13	  
1	  
MMT8	  (0.7)	  	  
PhGA	  (0.7)	  	  
PaGA	  (0.6)	  	  
2	   Skin	  DAS	  (0.4)	  	  
JDMAI5	   2	   0.3	  
1	  
CMAS	  (0.9)	  	  
PhGA	  (0.6)	  	  
PaGA	  (0.5)	  	  
2	   Skin	  VAS	  (0.6)	  	  
JDMAI6	   2	   0.1	   1	  
CMAS	  (0.8)	  	  
PhGA	  (0.7)	  	  
PaGA	  (0.5)	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2	   Skin	  DAS	  (0.5)	  	  
	  	  
Discriminant	   validity.	   The	   JDMAI	   showed	   strong	   ability	   to	   discriminate	  
patients	  judged	  as	  being	  in	  the	  states	  of	  inactive	  disease	  or	  low,	  moderate	  or	  high	  
disease	   activity	   by	   the	   physician	   (p	   <	   0.001).	   The	   JDMAI	   discriminated	   well	  
between	  patients	  whose	  parents	  were	  satisfied	  or	  not	  satisfied	  with	  the	  course	  of	  
their	  child’s	  illness	  (p	  <	  0.001)	  (see	  Figure	  1	  for	  the	  results	  regarding	  JDMAI1	  and	  
JDMAI2).	  For	  complete	  results	  see	  the	  Appendix	  (page	  46	  onward).	  	  
	  
Figure	  1.	  Assessment	  of	  the	  ability	  of	  JDMAI1	  and	  JDMAI2	  to	  discriminate	  patients	  
judged	  as	  being	  in	  the	  states	  of	  inactive	  disease	  or	  low,	  moderate	  or	  high	  disease	  
activity	  by	  the	  physician,	  and	  between	  patients	  whose	  parents	  were	  satisfied	  or	  
not	  satisfied	  with	  the	  course	  of	  their	  child’s	  illness	  in	  the	  Routine	  sample.	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Responsiveness	  to	  change.	  In	  the	  JDM	  trial	  sample,	  the	  SRM	  values	  were	  
good	  for	  both	  responders	  and	  non-­‐responders,	  although	  greater	  for	  the	  former	  
group	  (2.9-­‐3.1	  vs	  1.0-­‐1.1).	  In	  the	  Routine	  sample,	  the	  SRM	  was	  good	  (0.8–1.1)	  in	  
patients	   judged	   as	   improved	   and	  moderate	   (0.7–0.8)	   in	   patients	   judged	   as	   not	  




Table	   8.	   Standardized	   response	   mean	   of	   the	   six	   JDMAI	   versions	   in	   patients	  
classified	  as	  responders	  or	  non-­‐responders	  at	  6	  months	  in	  the	  JDM	  trial	  sample.	  	  
	  
	   Responders	   Non	  responders	  
JDMAI1	   3.07	   1.06	  
JDMAI2	   2.97	   1.00	  
JDMAI3	   3.12	   1.08	  
JDMAI4	   3.00	   1.00	  
JDMAI5	   2.96	   1.08	  
JDMAI6	   2.90	   0.97	  
	  	  
Table	  9.	  Standardized	  response	  mean	  of	  the	  six	  JDMAI	  versions	  in	  patients	  judged	  
subjectively	   as	   improved	   or	   not	   improved	   after	   6	  months	   of	   follow-­‐up	   by	   the	  
caring	  physician	  in	  the	  Routine	  sample.	  
	  
	   Improved	   	  Not	  improved	  
JDMAI1	   1.06	  	  	   0.78	  	  	  
JDMAI2	   0.97	  	  	   0.71	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JDMAI3	   1.14	  	  	   0.79	  	  	  
JDMAI4	   1.07	  	  	   0.71	  	  	  
JDMAI5	   0.92	  	  	   0.74	  	  	  





We	  have	  described	  herein	  the	  development	  of	  the	  first	  composite	  disease	  
activity	  score	  for	  JDM	  and	  provided	  preliminary	  evidence	  of	  its	  validity.	  The	  JDMAI	  
combines	  the	  four	  key	  measures	  of	  disease	  activity	  in	  JDM	  (PhGA,	  PaGA,	  muscle	  
strength	  and	  skin	  disease	  activity)	  into	  a	  single	  continuous	  measure.	  The	  score	  of	  
the	   JDMAI	   results	   from	   the	   arithmetic	   sum	   of	   the	   scores	   of	   each	   individual	  
component,	  which	  makes	  its	  calculation	  simple	  and	  quick.	  The	  PhGA	  and	  PaGA	  are	  
both	  measured	   on	   a	   VAS,	  which	   is	   preferentially	  measured	   on	   a	   21-­‐numbered	  
circle	  scale	  [45].	  Because	  there	  are	  no	  universally	  agreed	  instruments	  to	  quantify	  
muscle	  strength	  and	  skin	  disease	  in	  JDM,	  we	  tested	  six	  different	  versions	  of	  the	  
JDMAI,	  which	  included	  three	  muscle	  strength	  measures	  (MMT8,	  CMAS	  and	  hMC)	  
and	   two	   skin	   assessment	   scales	   (a	   skin	   disease	   activity	   VAS	   and	   the	   skin	  
component	  of	   the	  DAS).	   To	  make	   the	   score	  of	   the	   three	  muscle	   strength	   tools	  
consistent	  and	  reduce	  the	  potential	  that	  it	  might	  dominate	  the	  composite	  index,	  
the	  score	  of	  the	  three	  instruments	  was	  converted	  to	  a	  0-­‐10,	  decile-­‐based,	  scale.	  
Also	  for	  sake	  of	  consistency,	  scores	  were	  reversed	  to	  give	  them	  the	  same	  direction	  
(i.e.	  0	  =	  best	  to	  10	  =	  worst)	  as	  the	  other	  JDMAI	  components.	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Validation	   procedures	  were	   conducted	   on	   three	  multinational	   datasets,	  
comprising	  a	  total	  of	  627	  patients	  included	  in	  a	  research	  study,	  in	  a	  randomized	  
clinical	  trial,	  or	  followed	  up	  during	  routine	  clinical	  care.	  Altogether,	  these	  patients	  
are	   likely	   representative	   of	   the	   entire	   spectrum	   of	   children	   with	   JDM	   seen	   in	  
paediatric	  rheumatology	  centres	  worldwide.	  In	  validation	  analyses,	  the	  JDMAI	  was	  
found	  to	  possess	   face	  and	  content	  validity,	  good	  construct	  validity,	   satisfactory	  
internal	  consistency,	  fair	  responsiveness	  to	  clinically	  important	  change	  over	  time	  
and	   strong	   discriminative	   validity.	   Importantly,	   though	   not	   unexpectedly,	  
exploratory	  factor	  analysis	  showed	  that	  both	  PhGA	  and	  PaGA	  are	  mostly	  driven	  by	  
the	  severity	  of	  muscle	   impairment,	  and	  that	  skin	  disease	  constitutes	  a	  separate	  
disease	   domain.	   This	   finding	   suggests	   the	   need	   for	   future	   evaluations	   of	   the	  
relative	   impact	   of	  muscle	   and	   skin	   symptoms	  on	   physician’s	   and	   parent’s	   (and	  
patient’s)	  perception	  of	  disease	  burden.	  The	  high	  SRM	  values	  in	  responders	  in	  the	  
JDM	  trial	  sample	  suggest	  that	  the	  JDMAI	  is	  potentially	  applicable	  in	  therapeutic	  
studies.	   That	   construct	   validity	   and	   internal	   consistency	   were	   greater	   in	   the	  
Routine	  dataset	  indicate	  that	  it	  is	  also	  suited	  for	  use	  in	  daily	  practice.	  
Overall,	   the	   six	   versions	   of	   the	   JDMAI	   showed	   similar	   performance	   in	  
validation	   analyses.	   They	   can,	   therefore,	   be	   considered	   equally	   suitable	   and	  
reliable.	   However,	   there	   are	   some	   differences	   in	   the	  measures	   utilized	   for	   the	  
assessment	  of	  muscle	  strength	  and	  skin	  disease	  that	  are	  worth	  emphasizing.	  The	  
MMT8,	  included	  in	  JDMAI3	  and	  JDMAI4,	  and	  the	  CMAS,	  included	  in	  JDMAI5	  and	  
JDMAI6,	  are	  established	  key	  measures	  of	  muscle	  strength	   in	  children	  with	   JDM	  
[11,	  12].	  However,	  it	  has	  been	  argued	  that	  both	  instruments	  have	  limitations:	  the	  
MMT8	  lacks	  assessment	  of	  abdominal	  muscles,	  which	  are	  a	  major	  site	  of	  muscle	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disease	   in	   JDM,	   and	   the	   CMAS	   is	   lengthy	   and	   requires	   proper	   equipment	   to	  
complete	  the	  entire	  test.	  We	  have	  recently	  devised	  and	  tested	  a	  hybrid	  measure	  
of	  muscle	  strength	  for	  JDM	  (the	  hMC),	  which	  combines	  the	  whole	  MMT8	  with	  3	  
of	  the	  14	  items	  of	  the	  CMAS	  and	  is	  thought	  to	  be	  more	  complete	  than	  the	  MMT8	  
and	  more	  feasible	  than	  the	  CMAS	  [30].	  This	  tool	  is	  included	  in	  JDMAI1	  and	  JDMAI2.	  	  
Several	   measures	   have	   been	   proposed	   to	   assess	   skin	   disease	   in	   JDM,	  
including	  the	  original	  and	  abbreviated	  Cutaneous	  Assessment	  Tool	  (CAT)	  [46,	  47],	  
the	  DAS	  skin	  [27],	  the	  Myositis	  Intention	  to	  Treat	  Activity	  Index	  (MITAX)	  [31],	  and	  
the	   Cutaneous	   Dermatomyositis	   Disease	   Area	   and	   Severity	   Index	   (CDASI)	   [48].	  
However,	  none	  of	  these	  tools	  have	  been	  universally	  embraced	  [49].	  We	  opted	  for	  
the	  DAS	  skin	  (included	  in	  JDMAI2,	  JDMAI4	  and	  JDMAI6)	  and	  VAS	  skin	  (included	  in	  
JDMAI1,	   JDMAI3	   and	   JDMAI5)	   because	  we	   thought	   they	  were	  most	   suitable	   in	  
terms	  of	  ease	  of	  use	  and	  quantitative	  measurement	  properties.	  Notably,	  the	  VAS	  
has	  the	  advantage	  of	  being	  expressed	  on	  the	  same	  0-­‐10	  scale	  as	  the	  other	  JDMAI	  
items,	  whereas	  the	  DAS	  skin	  score	  ranges	  from	  0	  to	  9.	  It	  is,	  however,	  anticipated	  
that	  the	  JDMAI	  might	  need	  to	  be	  revised	  when	  new	  well-­‐designed	  and	  validated	  
skin-­‐specific	  instruments	  for	  JDM	  will	  become	  available	  [50].	  In	  the	  meantime,	  we	  
favour	  the	  JDMAI1,	  as	  it	  includes	  a	  feasible	  muscle	  strength	  tool	  and	  the	  simplest	  
skin	  assessment	  measure.	  
This	   study	   has	   some	   limitations.	   We	   recognize	   that	   the	   new	   tool	   was	  
developed	   by	   a	   restricted	   group	   of	   experts	   based	   on	   their	   experience	   in	   the	  
assessment	  of	  children	  with	  JDM	  and	  the	  review	  of	  the	  pertinent	  literature	  and	  
that	  a	  formal	  Delphi	  survey	  was	  not	  carried	  out.	  The	  JDMAI	  assesses	  specifically	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the	  two	  major	  systems	  affected	  in	  JDM	  (skeletal	  muscles	  and	  skin),	  but	  neglects	  
other	  potentially,	   though	   less	   commonly,	   involved	  organs/systems,	   such	  as	   the	  
gastrointestinal,	   pulmonary	   and	   cardiac.	   It	   is,	   however,	   assumed	   that	   active	  
disease	  in	  these	  organs	  is	  incorporated,	  at	  least	  in	  part,	  in	  PhGA	  and	  PaGA.	  In	  the	  
Routine	   dataset,	   the	   proportion	   of	   patients	   with	   constitutional	   features	   and	  
articular,	  pulmonary,	  gastrointestinal	  and	  cardiac	  involvement	  was	  89.6%,	  46.6%,	  
17.8%,	  16.2%	  and	  3.7%,	  respectively.	  This	   information	  was	  not	  available	  for	  the	  
other	  two	  datasets.	  We	  acknowledge	  that	  the	  choice	  to	  transform	  muscle	  score	  
values	   in	   deciles	   is	   arbitrary	   and	   that	   its	   validity	   should	   be	   further	   tested.	   The	  
design	  of	  the	  study	  did	  not	  allow	  us	  to	  test	  the	  inter-­‐	  and	  intra-­‐observer	  reliability	  
of	   the	   JDMAI.	   This	   property	   was,	   however,	   demonstrated	   for	   all	   individual	  
measures	  included	  in	  the	  tool	  [11,	  12].	  Due	  to	  the	  lack	  of	  longitudinal	  assessments,	  
we	  could	  not	  investigate	  the	  capacity	  of	  the	  JDMAI	  to	  predict	  disease	  outcomes,	  
such	  as	  continued	  activity,	  cumulative	  damage,	  or	  functional	  disability.	  	  
In	  conclusion,	  we	  have	  developed	  a	  new	  composite	  disease	  activity	  score	  
for	   JDM,	  which	   is	   composed	   of	   the	   four	   key	   disease	   activity	  measures	   for	   this	  
disease.	   In	   validation	   analyses,	   the	   instrument	   was	   found	   to	   possess	   good	  
measurement	  properties,	  which	  indicates	  that	  it	  is	  applicable	  in	  both	  clinical	  and	  
research	   settings.	   The	   final	   version	   of	   the	   JDMAI	   will	   be	   selected	   after	   its	  
prospective	   validation,	  which	   is	   currently	   under	  way.	   Another	   key	   objective	   of	  
future	  analyses	  is	  to	  define	  cutoffs	  in	  the	  score	  that	  correspond	  to	  the	  states	  of	  
inactive	  disease	  and	  low,	  moderate	  and	  high	  disease	  activity	  in	  JDM.	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  THIRD	  PART:	  PRELIMINARY	  PROSPECTIVE	  
VALIDATION	  OF	  THE	  JUVENILE	  DERMATOMYOSITIS	  




In	   parallel	   to	   the	   large	   scale	   validation	   carried	  out	   on	   the	  multinational	  
sample	  of	  patients	  so	  far	  described,	  a	  prospective	  validation	  of	  the	  new	  tool	  has	  
been	   conducted	   on	   a	   sample	   of	   JDM	   patients	   seen	   in	   clinical	   practice	   and	  
specifically	  enrolled	  for	  the	  purpose	  of	  this	  study.	  	  
	  
Patients	  and	  Methods	  
	  
A	  total	  of	  57	  JDM	  patients,	  either	  at	  disease	  onset	  or	  at	  a	  follow-­‐up	  visit,	  a	  
median	  of	  2	  years	  after	  disease	  onset,	  were	  consecutively	  enrolled.	  Each	  patient	  
received	   a	   retrospective	   assessment	   and	   a	   cross-­‐sectional	   evaluation	   at	   study	  
entry.	   Twenty-­‐five	   patients	   also	   underwent	   a	   second	   (prospective)	   assessment	  
after	  a	  median	  of	  3.6	  months	  from	  study	  entry.	  Nearly	  half	  of	  the	  patients	  (to	  be	  
precise,	  30),	  were	  evaluated	  by	  the	  examinee	  between	  October	  2015	  and	  March	  
2016,	   during	   her	   fellowship	   spent	   at	   the	   Rheumatology	   Department	   of	   Great	  
Ormond	  Street	  Hospital	  in	  London.	  The	  rest	  of	  the	  patients	  were	  enrolled	  by	  the	  
candidate	  herself	  from	  October	  2016	  onward,	  at	  the	  Rheumatology	  Department	  
of	  Istituto	  Giannina	  Gaslini	  in	  Genoa,	  mostly	  when	  admitted	  to	  the	  ward.	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At	  every	  study	  visit,	  the	  following	  evaluations	  were	  collected:	  	  
a)   demographic	  data:	  sex,	  birth	  date,	  disease	  onset	  date,	  date	  of	  first	  
visit	  at	  the	  centre	  for	  JDM,	  date	  of	  study	  visit;	  
b)   retrospective	  data:	  JDM	  diagnostic	  criteria	  that	  were	  present	  at	  the	  
time	  of	  diagnosis,	  date	  of	  diagnosis,	  main	  disease	  manifestations	  prior	  to	  study	  
visit,	  patient	  drug	  therapy	  prior	  to	  study	  visit,	  Myositis	  Specific	  Antibodies	  (MSA)	  
and	  Antinuclear	  Antibodies	  (ANA)	  status;	  	  
c)   cross-­‐sectional	  data,	  as	  follows:	  	  
•   muscle	  disease	  activity	  assessment:	  MMT8,	  CMAS,	  hMC,	  muscular	  
domain	  of	  DAS,	  muscle	  VAS;	  	  	  
•   skin	  disease	  activity	  assessment:	  skin	  domain	  of	  DAS,	  skin	  VAS,	  a	  
modified	   version	   of	   the	   skin	   section	   of	   the	  Myositis	   Intention	   to	   Treat	   Activity	  
Index	   or	  MITAX	   (considering	   all	   its	   original	   11	   items	   but	   evaluating	   them	   in	   a	  
quantitative	   instead	  of	   in	  a	  categorical	  way	  -­‐	  namely,	  on	  a	  0-­‐4	  scale	  where:	  0	  =	  
absent,	  1	  =	  mild,	  2	  =	  moderate,	  3	  =	  severe,	  4	  =	  very	  severe);	  	  
•   physician’s	  global	  assessment	  of	  overall	  disease	  activity	  (PhGA)	  on	  
a	  visual	  analogue	  scale	  (VAS)	  (where	  0	  =	  no	  activity	  and	  10	  =	  maximum	  activity);	  	  
•   evaluation	   of	   disease	   status	   by	   the	   physician	   (inactive	  
disease/continued	   activity/flare	   -­‐	   if	   continued	   activity/flare:	   level	   of	   disease	  
activity,	  defined	  as	  minimal,	  moderate	  or	  high);	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•   evaluation	  of	  disease	   course	   from	  previous	  visit	  by	   the	  physician	  
(much	   improved/slightly	   improved/stable-­‐unchanged/slightly	   worsened/much	  
worsened/1st	  visit);	  	  
•   laboratory	  results:	  CK,	  LDH,	  ALT,	  AST,	  ESR;	  
•   a	  detailed	  record	  of	  patient	  drug	  therapy	  at	  study	  visit;	  	  
•   evaluation	   of	   cumulative	   damage	   through	   the	   Myositis	   Damage	  
Index	  (MDI).	  	  
Parent-­‐reported	  outcomes	  were	  collected	  through	  the	  administration	  of	  a	  
multidimensional	   questionnaire	   taking	   into	   account	   the	   following	   items:	  
functional	  ability,	  pain	  VAS,	  fatigue	  VAS,	  symptoms	  in	  the	  last	  four	  weeks,	  global	  
evaluation	   of	   disease	   activity,	   evaluation	   of	   disease	   status	   from	   previous	   visit,	  
evaluation	  of	  disease	  course	  from	  previous	  visit,	  ongoing	  therapies	  and	  possible	  
side	  effects,	  compliance	  to	  treatments,	  possible	  school	  problems,	  quality	  of	  life,	  
parent’s	  global	  assessment	  of	  patient’s	  overall	  wellbeing	  (PaGA)	  on	  a	  VAS	  (where	  
0	  =	  best	  and	  10	  =	  worst),	  and	  the	  so	  called	  “parent	  acceptable	  symptom	  state”	  
(PASS)	  [43].	  If	  appropriate	  (that	  is,	  above	  7-­‐8	  years	  of	  age),	  the	  same	  questionnaire	  
was	  administered	  to	  patients	  as	  well.	  	  
Similarly	  to	  what	  already	  done	  during	  the	  preliminary	  validation	  phase	  of	  
the	   new	   tool,	   the	   construct	   validity,	   internal	   consistency,	   responsiveness	   to	  
change,	  and	  discriminant	  ability	  of	  the	  six	  different	  versions	  of	  the	  JDMAI	  were	  
assessed	  on	  the	  prospective	  sample	  of	  patients.	  Validation	  of	  the	  JDMAI	   in	  this	  
sample	  was	  conducting	  according	  to	  the	  same	  procedures	  described	  in	  the	  Second	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Part	  of	  the	  work	  (see	  page	  14	  for	  details).	  	  
Results	  
	  
The	  main	  demographic	  and	  clinical	  features	  of	  the	  prospective	  sample	  at	  
baseline	  are	  shown	  in	  Table	  10,	  while	  Table	  11	  shows	  patients’	  treatment	  history	  
up	  to	  baseline	  visit.	  	  






N	  =	  57	  
	   Min	  –	  Max	   Median	  (IQR)	  
Sex	  (Female)	  	  -­‐	  	  n.	  (%)	   -­‐	   31	  (54.4%)	  
Caucasian,	  yes	  	  -­‐	  	  n.	  (%)	   -­‐	   48	  (84.2%)	  
ANA,	  positive	  	  -­‐	  	  n.	  (%)	   -­‐	   15/23	  (65.2%)	  
MSA,	  positive	  	  -­‐	  	  n.	  (%)	   -­‐	   12/18	  (66.7%)	  
Age	  at	  disease	  onset	  (years)	   -­‐	   5.7	  (2.9	  -­‐	  8.2)	  	  	  
Age	  at	  diagnosis	  (years)	   -­‐	   6.4	  (3.7	  -­‐	  8.6)	  
Age	  at	  1st	  visit	  (years)	   -­‐	   8.6	  (6.2	  -­‐	  11.8)	  
Disease	  duration	  from	  onset	  to	  
study	  visit	  (years)	  
-­‐	   2	  (0.6	  -­‐	  4.5)	  	  	  
Physician	  Global	  Activity	  VAS	   0-­‐10	   2	  (0.7	  -­‐	  3.6)	  	  	  
Muscle	  activity	  VAS	   0-­‐10	   0.5	  (0	  -­‐	  4)	  	  	  
Skin	  activity	  VAS	  	   0-­‐10	   1.5	  (0.5	  -­‐	  2.9)	  
DAS	  -­‐	  muscle	  section	   0-­‐11	   2.5	  (0	  -­‐	  5)	  	  	  
	   33	  
DAS	  -­‐	  skin	  section	   0-­‐9	   5	  (4	  -­‐	  5)	  
DAS	  Total	  score	   0-­‐20	   7	  (4	  -­‐	  11)	  	  	  
MMT8	   0-­‐80	   76	  (66	  -­‐	  80)	  	  	  
CMAS	   0-­‐52	   48	  (39	  -­‐	  52)	  	  	  
hMC	   0-­‐100	   91.5	  (79	  -­‐	  100)	  	  	  
ESR,	  mm/h	   0-­‐10*	   8.9	  (5	  -­‐	  21.1)	  	  	  
Creatine	  Kinase,	  U/L	   0	  –	  150*	   69	  (5.8	  -­‐	  124)	  	  	  
Lactate	  Dehydrogenase	   84-­‐480*	   441	  (241.5	  -­‐	  667)	  	  	  
Alanine	  Transaminase	   0-­‐40*	   33	  (21	  -­‐	  50)	  	  	  
Aspartate	  Transaminase	   0-­‐40*	   43.4	  (28.6	  -­‐	  57)	  	  	  
MDI	   0-­‐35	   0	  (0	  -­‐	  1)	  	  	  
MDI:	  	  	  0	  	  	  (n,	  %)	   	   	  19/27	  (70.4%)	  
	  	  	  	  	  	  	  	  	  	  	  	  1-­‐2	  (n,	  %)	   	   4/27	  (14.8%)	  
	  	  	  	  	  	  	  	  	  	  	  ≥	  3	  to	  8	  (n,	  %)	   	   	  4/27	  (14.8%)	  
Parent	  Global	  Assessment	  (VAS)	   0-­‐10	   3	  (0.6	  -­‐	  5.9)	  	  	  
Pain	  VAS	   0-­‐10	   1	  (0	  -­‐	  4)	  	  	  
Fatigue	  VAS	   0-­‐10	   2.5	  (0	  -­‐	  7.5)	  
PASS,	  yes	  	  	  (n,	  %)	   	   8/23	  (34.8%)	  
*	  Normal	  values	  of	  the	  corresponding	  laboratory	  analysis;	  IQR	  =	  Interquartile	  Range;	  NA	  
=	  Not	  Available.	  	  
 
Table	  11.	  Treatment	  history	  up	  to	  baseline	  visit.	  
	  
	   Prospective	  sample	  	  (N	  =	  57)	  
	   n.	  (%)	  
Oral	  corticosteroids	   43	  (75.4%)	  
	   34	  
Intravenous	  corticosteroids	   	  	  6	  (10.5%)	  
Corticosteroids	  pulses	   30	  (52.6%)	  
Oral	  Cyclophosphamide	   	  	  3	  (5.7%)	  
Intravenous	  Cyclophosphamide	   11	  (19.3%)	  
Oral	  Methotrexate	   11	  (19.3%)	  
Subcutaneous	  Methotrexate	   38	  (66.7%)	  
Oral	  Cyclosporin	   	  	  9	  (15.8%)	  
Intravenous	  Infliximab	   	  	  7	  (12.3%)	  
Intravenous	  Rituximab	   	  	  3	  (5.3%)	  
Intravenous	  Immunoglobulin	   21	  (36.8%)	  
Oral	  Hydroxicloroquine	   18	  (31.6%)	  
Oral	  Azathioprine	   	  	  6	  (10.5%)	  
Other	   	  	  5	  (8.8%)	  
	  
The	  following	  table	  (Table	  12)	  demonstrates	  the	  descriptives	  of	  the	  6	  
versions	  of	  JDMAI	  at	  baseline.	  	  
	  
Table	  12.	  Descriptives	  of	  the	  6	  versions	  of	  JDMAI	  at	  baseline.	  
	  
	   Score	  range	  
(min	  –	  max)	  
Median	  
(IQR)	  
JDMAI-­‐1	   0	  -­‐	  40	   8.4	  (2.8	  -­‐	  14.4)	  	  	  
JDMAI-­‐2	   0	  -­‐	  39	   11	  (5.5	  -­‐	  17.9)	  
JDMAI-­‐3	   0	  -­‐	  40	   8.4	  (2.8	  -­‐	  14.4)	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JDMAI-­‐4	   0	  -­‐	  39	   11.2	  (5.5	  -­‐	  17.9)	  	  	  
JDMAI-­‐5	   0	  -­‐	  40	   8.1	  (2.8	  -­‐	  14.4)	  	  	  
JDMAI-­‐6	   0	  -­‐	  39	   11	  (5.5	  -­‐	  17.9)	  	  	  
IQR	  =	  Interquartile	  Range. 
	  
Construct	  validity.	  Spearman’s	  correlations	  between	  the	  six	  versions	  of	  the	  
JDMAI	  and	  the	  JDM	  clinical	  measures	  not	  included	  in	  the	  score	  are	  shown	  in	  Table	  
13.	   In	   the	   prospective	   sample,	   correlations	   for	   JDMAI	   were	   high	   with	   muscle	  
activity	  VAS,	  DAS	  muscle,	  DAS	  total,	  pain	  VAS,	  and	  fatigue	  VAS.	  The	  correlations	  
with	  the	  skin	  index	  not	  contained	  in	  the	  specific	  version	  of	  the	  tool	  itself	  (that	  is,	  
skin	  VAS	  or	  cutaneous	  domain	  of	  DAS)	  turned	  out	  to	  be	  high	  as	  well.	  As	  expected,	  
JDMAI	   correlations	   with	   laboratory	   parameters	   and	   MDI	   came	   out	   to	   be	  
moderate-­‐to-­‐low.	  	  
	  
Table	  13.	  Spearman’s	  Rank	  correlation	  between	  the	  six	  different	  versions	  of	  
the	  JDMAI	  and	  the	  main	  JDM	  outcome	  measures	  at	  baseline.	  
	  
	   JDMAI1	   JDMAI2	   JDMAI3	   JDMAI4	   JDMAI5	   JDMAI6	  
Muscle	  activity	  VAS	   0.84	  	  	   0.84	  	  	   0.83	  	  	   0.84	  	  	   0.84	  	  	   0.84	  	  	  
Skin	  activity	  VAS	   -­‐	   0.76	  	  	   -­‐	   0.76	  	  	   -­‐	   0.75	  	  	  
DAS	  -­‐	  muscle	  section	   0.79	  	  	   0.80	  	  	   0.78	  	  	   0.79	  	  	   0.79	  	  	   0.79	  	  	  
DAS	  -­‐	  skin	  section	   0.72	  	  	   -­‐	   0.74	  	  	   -­‐	   0.72	  	  	   -­‐	  
Disease	  Activity	  Score	  (DAS)	   0.87	  	  	   0.89	  	  	   0.86	  	  	   0.88	  	  	   0.86	  	  	   0.88	  	  	  
MMT	  8	   -­‐0.84	  	  	   -­‐0.85	  	  	   -­‐	   -­‐	   -­‐0.83	  	   -­‐0.83	  	  	  
CMAS	   -­‐0.79	  	  	   -­‐0.79	  	  	   -­‐0.77	  	  	   -­‐0.77	  	  	   -­‐	   -­‐	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Hybrid	  MMT/CMAS	  (hMC)	  	   -­‐	   -­‐	   -­‐0.82	  	  	   -­‐0.83	  	  	   -­‐0.83	  	  	   -­‐0.83	  	  	  
Creatine	  kinase,	  U/L	   0.21	  	  	   0.21	  	  	   0.2	  	  	   0.22	  	  	   0.23	  	  	   0.23	  	  	  
LDH,	  U/L	   0.5	  	  	   0.49	  	  	   0.49	  	  	   0.5	  	  	   0.52	  	  	   0.52	  	  	  
ALT,	  U/L	   0.44	  	  	   0.43	  	  	   0.42	  	  	   0.43	  	  	   0.45	  	  	   0.45	  	  	  
AST,	  U/L	   0.49	  	  	   0.48	  	   0.48	  	  	   0.48	  	  	   0.49	  	  	   0.48	  	  	  
ESR,	  mm/h	   0.38	  	  	   0.35	  	  	   0.38	  	  	   0.35	  	  	   0.37	  	  	   0.35	  	  
MDI	   -­‐0.04	  	  	   -­‐0.05	  	  	   -­‐0.04	  	  	   -­‐0.05	  	  	   -­‐0.05	  	  	   -­‐0.05	  	  	  
Pain	  VAS	   0.74	  	  	   0.71	  	  	   0.74	  	  	   0.74	  	  	   0.73	  	  	   0.73	  	  	  
Fatigue	  VAS	   0.88	  	  	   0.89	  	  	   0.88	  	  	   0.88	  	  	   0.89	  	  	   0.89	  	  	  
 
	  
Internal	  consistency.	  Cronbach’s	  alpha	  values	  turned	  out	  to	  be	  very	  high	  
(0.884-­‐0.900)	  for	  all	  versions	  of	  JDMAI	  (see	  Table	  14	  for	  complete	  results).	  	  
	  
Table	  14.	  Internal	  consistency:	  Cronbach’s	  Alpha	  (baseline	  visit).	  
	  
	   Prospective	  sample	  
JDMAI	  1	   0.897	  	  	  
JDMAI	  2	   0.884	  	  	  
JDMAI	  3	   0.900	  	  
JDMAI	  4	   0.890	  	  	  
JDMAI	  5	   0.899	  	  
JDMAI	  6	   0.884	  
  
Responsiveness	   to	   change.	   In	   the	   prospective	   patient	   sample,	   the	   SRM	  
values	  were	  greater	  for	  the	  patients	  judged	  as	  improved	  by	  the	  physician	  or	  the	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parent	  (SRM	  =	  0.83-­‐1.15)	  than	  for	  the	  ones	  judged	  as	  not	  improved	  or	  stable	  (SRM	  
=	  0.02-­‐0.51).	  These	  results	  are	  shown	  in	  Table	  15.	  	  
	  
Table	  15.	  Standardized	  response	  mean	   (SRM)	  of	  different	   JDMAI	  versions	   in	  all	  
patients	  and	  in	  the	  patients	  judged	  as	  improved	  according	  to	  the	  physician’s	  and	  
parents’	  opinion	  in	  the	  Prospective	  sample	  after	  a	  median	  of	  3.6	  months	  of	  follow-­‐
up.	  
	  
	   All	  patients	   Physician’s	  opinion	   Parents’	  opinion	  
	   	   Improved	   Worsened/Stable	  	   Improved	  	   Worsened/Stable	  
JDMAI	  1	   0.8	   1.07	   0.02	   0.89	   0.49	  
JDMAI	  2	   0.76	   1.12	   0.21	   0.87	   0.37	  
JDMAI	  3	   0.8	   1.08	   0.02	   0.96	   0.51	  
JDMAI	  4	   0.78	   1.15	   0.21	   0.93	   0.40	  
JDMAI	  5	   0.78	   1.04	   0.02	   0.84	   0.44	  
JDMAI	  6	   0.74	   1.07	   0.21	   0.83	   0.33	  
	  
	  
Discriminant	   ability.	   The	   JDMAI	   showed	   strong	   ability	   to	   discriminate	  
patients	  judged	  as	  being	  in	  the	  states	  of	  inactive	  disease	  or	  low,	  moderate	  or	  high	  
disease	  activity	  by	  the	  physician	  (p	  <	  0.001)	  or	  by	  the	  parent	  (p	  =	  0.011-­‐0.031).	  See	  
Table	  16,	  Table	  17	  and	  Table	  18	  for	  details.	  The	  JDMAI	  discriminated	  well	  between	  
patients	  whose	  parents	  were	  satisfied	  or	  not	  satisfied	  of	  the	  course	  of	  their	  child’s	  
illness	  (p	  ≤	  0.001).	  These	  results	  are	  shown	  in	  Table	  19.	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Table	  16.	  Assessment	  of	   the	  ability	  of	  different	   JDMAI	   versions	   to	  discriminate	  
patients	   judged	   as	   being	   in	   the	   states	   of	   continuous	   activity/flare	   or	   inactive	  
disease	   by	   the	   physician	   in	   all	   visits	   in	   the	   Prospective	   dataset	   in	   which	   this	  
evaluation	  was	  available	  (n=69).	  
	  
	   	   N	   Median	  [IQR]	   Min	  -­‐	  Max	   P	  
JDMAI	  1	   	  Continuous	  activity/flare	   56	   9.9	  [5.3	  -­‐	  14.4]	   2.5	  -­‐	  29.8	   <	  0.0001	  
	   	  Inactive	   19	   1.3	  [0.7	  -­‐	  2.2]	   0	  -­‐	  7.7	   	  
JDMAI	  2	   	  Continuous	  activity/flare	   56	   12.6	  [8.3	  -­‐	  17.7]	   4	  -­‐	  30.1	   <	  0.0001	  
	   	  Inactive	   19	   4.3	  [2.7	  -­‐	  5]	   0	  -­‐	  10	   	  
JDMAI	  3	   	  Continuous	  activity/flare	   57	   9.8	  [5.5	  -­‐	  14.4]	   2.5	  -­‐	  29.8	   <	  0.0001	  
	   	  Inactive	   19	   1	  [0.4	  -­‐	  2]	   0	  -­‐	  7.7	   	  
JDMAI	  4	   	  Continuous	  activity/flare	   57	   12.2	  [9.1	  -­‐	  17.5]	   4	  -­‐	  30.1	   <	  0.0001	  
	   	  Inactive	   19	   4	  [2.5	  -­‐	  5]	   0	  -­‐	  10	   	  
JDMAI	  5	   	  Continuous	  activity/flare	   56	   10.1	  [5.1	  -­‐	  14.2]	   2.5	  -­‐	  31	   <	  0.0001	  
	   	  Inactive	   19	   1.3	  [0.7	  -­‐	  2.5]	   0	  -­‐	  7.7	   	  
JDMAI	  6	   	  Continuous	  activity/flare	   56	   13.2	  [8.2	  -­‐	  17.5]	   4	  -­‐	  32.5	   <	  0.0001	  
	   	  Inactive	   19	   4.3	  [2.7	  -­‐	  5]	   0	  -­‐	  10	   	  
IQR	  =	  Interquartile	  Range;	  P:	  Non	  parametric	  test:	  Mann-­‐Whitney	  U	  test.	  
	  
Table	  17.	  Assessment	  of	  the	  ability	  of	  different	  JDMAI	  versions	  to	  discriminate	  
patients	  judged	  as	  being	  in	  the	  states	  of	  persistent	  activity/relapse	  or	  remission	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by	  the	  parents’	  evaluation	  in	  all	  visits	  in	  the	  Prospective	  dataset	  in	  which	  this	  
evaluation	  was	  available	  (n=29).	  
	  
	   	   N	   Median	  [IQR]	   Min	  -­‐	  Max	   P	  
JDMAI	  1	   	  Persistent	  activity/relapse	   26	   10.6	  [5	  -­‐	  14]	   1.6	  -­‐	  28	   0.016	  
	   	  Remission	   9	   2.5	  [1	  -­‐	  6.5]	   0	  -­‐	  15	   	  
JDMAI	  2	   	  Persistent	  activity/relapse	   26	   12.8	  [8.5	  -­‐	  16.5]	   4	  -­‐	  29.5	   0.031	  
	   	  Remission	   9	   6.5	  [2.5	  -­‐	  10.2]	   0	  -­‐	  18	   	  
JDMAI	  3	   	  Persistent	  activity/relapse	   27	   9.5	  [5	  -­‐	  14]	   1.6	  -­‐	  27	   0.011	  
	   	  Remission	   9	   2.5	  [0.5	  -­‐	  5.5]	   0	  -­‐	  15	   	  
JDMAI	  4	   	  Persistent	  activity/relapse	   27	   12	  [8.5	  -­‐	  16]	   4	  -­‐	  28.5	   0.027	  
	   	  Remission	   9	   5.5	  [2.5	  -­‐	  9.2]	   0	  -­‐	  18	   	  
JDMAI	  5	   	  Persistent	  activity/relapse	   26	   10.6	  [5	  -­‐	  14]	   1.6	  -­‐	  31	   0.013	  
	   	  Remission	   9	   2.5	  [1	  -­‐	  5.5]	   0	  -­‐	  15	   	  
JDMAI	  6	   	  Persistent	  activity/relapse	   26	   13.3	  [8.3	  -­‐	  16.5]	   4	  -­‐	  32.5	   0.029	  
	   	  Remission	   9	   6.5	  [2.5	  -­‐	  9.2]	   0	  -­‐	  18	   	  
IQR	  =	  Interquartile	  Range;	  P:	  Non	  parametric	  test:	  Mann-­‐Whitney	  U	  test.	  
	  
Table	   18.	   Assessment	   of	   the	   ability	   of	   different	   JDMAI	   versions	   to	   discriminate	  
patients	   judged	   as	   being	   in	   the	   states	   of	   high,	   moderate,	   minimal,	   or	   inactive	  
disease	   by	   the	   physician	   in	   all	   visits	   in	   the	   Prospective	   dataset	   in	   which	   this	  
evaluation	  was	  available	  (n=69).	  
	   	   N	   Median	  [IQR]	   Min	  -­‐	  Max	   p	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JDMAI	  1	   	  High	  disease	  activity	   4	   26.5	  [22.7	  -­‐	  28]	   20.5	  -­‐	  28	   <	  0.0001	  
	   	  Moderate	  disease	  activity	   29	   12.7	  [8.4	  -­‐	  16.7]	   2.7	  -­‐	  29.8	   	  
	   	  Minimal	  disease	  activity	   23	   5.5	  [4	  -­‐	  9.4]	   2.5	  -­‐	  13.5	   	  
	   	  Inactive	   19	   1.3	  [0.7	  -­‐	  2.2]	   0	  -­‐	  7.7	   	  
JDMAI	  2	   	  High	  disease	  activity	   4	   28.6	  [25.4	  -­‐	  29.4]	   22.8	  -­‐	  29.5	   <	  0.0001	  
	   	  Moderate	  disease	  activity	   29	   15	  [11.5	  -­‐	  19.8]	   5.5	  -­‐	  30.1	   	  
	   	  Minimal	  disease	  activity	   23	   8.5	  [6.6	  -­‐	  12.2]	   4	  -­‐	  17	   	  
	   	  Inactive	   19	   4.3	  [2.7	  -­‐	  5]	   0	  -­‐	  10	   	  
JDMAI	  3	   	  High	  disease	  activity	   4	   26	  [22.2	  -­‐	  27]	   19.5	  -­‐	  27	   <	  0.0001	  
	   	  Moderate	  disease	  activity	   29	   12.6	  [8.4	  -­‐	  15.7]	   2.7	  -­‐	  29.8	   	  
	   	  Minimal	  disease	  activity	   24	   5.9	  [4	  -­‐	  8.5]	   2.5	  -­‐	  13.5	   	  
	   	  Inactive	   19	   1	  [0.4	  -­‐	  2]	   0	  -­‐	  7.7	   	  
JDMAI	  4	   	  High	  disease	  activity	   4	   27.8	  [24.4	  -­‐	  28.9]	   21.8	  -­‐	  29.2	   <	  0.0001	  
	   	  Moderate	  disease	  activity	   29	   15.5	  [12	  -­‐	  18.8]	   5.5	  -­‐	  30.1	   	  
	   	  Minimal	  disease	  activity	   24	   9	  [6.6	  -­‐	  11.5]	   4	  -­‐	  17	   	  
	   	  Inactive	   19	   4	  [2.5	  -­‐	  5]	   0	  -­‐	  10	   	  
JDMAI	  5	   	  High	  disease	  activity	   4	   26.5	  [22.7	  -­‐	  30]	   21.5	  -­‐	  31	   <	  0.0001	  
	   	  Moderate	  disease	  activity	   29	   12.4	  [8.1	  -­‐	  15.7]	   2.7	  -­‐	  30.8	   	  
	   	  Minimal	  disease	  activity	   23	   5.2	  [4	  -­‐	  9.8]	   2.5	  -­‐	  13.5	   	  
	   	  Inactive	   19	   1.3	  [0.7	  -­‐	  2.5]	   0	  -­‐	  7.7	   	  
JDMAI	  6	   	  High	  disease	  activity	   4	   28.6	  [26	  -­‐	  30.8]	   23.8	  -­‐	  32.5	   <	  0.0001	  
	   	  Moderate	  disease	  activity	   29	   15.5	  [11.5	  -­‐	  18.8]	   5.5	  -­‐	  31.1	   	  
	   	  Minimal	  disease	  activity	   23	   8.3	  [6.6	  -­‐	  11.4]	   4	  -­‐	  17	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  Inactive	   19	   4.3	  [2.7	  -­‐	  5]	   0	  -­‐	  10	   	  
IQR	  =	  Interquartile	  Range;	  P:	  Non	  parametric	  analysis	  of	  variance:	  Kruskal-­‐Wallis	  test.	  
	  
Table	  19.	  Assessment	  of	   the	  ability	  of	  different	   JDMAI	  versions	   to	  discriminate	  
between	  patients	  whose	  parents	  were	  not	  satisfied	  or	  satisfied	  with	  the	  course	  of	  
their	  child’s	  illness	  in	  all	  visits	  in	  the	  Prospective	  dataset	  in	  which	  this	  evaluation	  
was	  available	  (n=29).	  
	  
	   	   N	   Median	  [IQR]	   Min	  -­‐	  Max	   P	  
JDMAI	  1	   	  Not	  satisfied	   19	   13	  [8	  -­‐	  18.5]	   4	  -­‐	  28	   <	  0.0001	  
	   	  Satisfied	   16	   4	  [1.3	  -­‐	  6.4]	   0	  -­‐	  11.5	   	  
JDMAI	  2	   	  Not	  satisfied	   19	   15	  [11.5	  -­‐	  22]	   4.5	  -­‐	  29.5	   0.0001	  
	   	  Satisfied	   16	   6.5	  [4.2	  -­‐	  9.8]	   0	  -­‐	  15.5	   	  
JDMAI	  3	   	  Not	  satisfied	   19	   13	  [8	  -­‐	  18.5]	   3.8	  -­‐	  27	   <	  0.0001	  
	   	  Satisfied	   17	   4	  [1.6	  -­‐	  6.6]	   0	  -­‐	  11.5	   	  
JDMAI	  4	   	  Not	  satisfied	   19	   15.5	  [12	  -­‐	  21.8]	   4.5	  -­‐	  28.5	   0.0001	  
	   	  Satisfied	   17	   6.5	  [4.3	  -­‐	  10.3]	   0	  -­‐	  15.5	   	  
JDMAI	  5	   	  Not	  satisfied	   19	   13.5	  [8	  -­‐	  20.5]	   4	  -­‐	  31	   <	  0.0001	  
	   	  Satisfied	   16	   4	  [1.3	  -­‐	  5.4]	   0	  -­‐	  12.5	   	  
JDMAI	  6	   	  Not	  satisfied	   19	   16	  [11.5	  -­‐	  23.8]	   4.5	  -­‐	  32.5	   <	  0.0001	  
	   	  Satisfied	   16	   6.5	  [4.2	  -­‐	  8.9]	   0	  -­‐	  15.5	   	  
IQR	  =	  Interquartile	  Range;	  P:	  Non	  parametric	  test:	  Mann-­‐Whitney	  U	  test.	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The	  following	  figure	  (Figure	  2)	  	  is	  the	  graphic	  representation	  of	  the	  ability	  
of	   JDMAI1	   to	   discriminate	   between	   patients	   judged	   as	   being	   in	   the	   state	   of	  
continued	  activity/flare	  or	   inactive	  disease	  by	   the	  physician	   (panel	  A),	  between	  
patients	  judged	  as	  being	  in	  the	  state	  of	  persistent	  activity/relapse	  or	  remission	  by	  
the	  parent	   (panel	  B),	  between	  patients	   judged	  as	  being	   in	   the	  state	  of	   inactive	  
disease	  or	  low,	  moderate	  or	  high	  disease	  activity	  by	  the	  physician	  (panel	  C),	  and	  
between	  patients	  whose	  parents	  were	  satisfied	  or	  not	  satisfied	  with	  the	  course	  of	  
their	  child’s	  illness	  (panel	  D)	  in	  the	  prospective	  sample.	  The	  other	  versions	  of	  the	  
tool	  revealed	  similar	  discriminant	  ability	  (see	  the	  Appendix	  for	  complete	  results,	  
page	  51	  onward).	  	  
	  
Figure	   2.	   Capacity	   of	   the	   JDMAI1	   to	   discriminate	   between	   activity	   states	   and	  
parent	  satisfaction/non	  satisfaction.	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Conclusions	  and	  possible	  future	  developments	  
	  
Validation	  analyses	  conducted	  on	  this	  prospective	  sample	  of	  57	  patients	  
followed	  up	  at	  two	  tertiary-­‐care	  paediatric	  rheumatology	  centers	  confirmed	  that	  
the	  JDMAI	  possesses	  good	  measurement	  properties	  and	  is	  a	  suitable	  and	  reliable	  
tool	   for	   the	  assessment	  of	  disease	  activity	   in	  children	  with	  JDM	  not	  only	   in	   the	  
research	  setting	  but	  also	  in	  clinical	  practice.	  Importantly,	  the	  new	  tool	  revealed	  a	  
strong	  capacity	  to	  capture	  the	  improvement	  of	  disease	  activity	  over	  time.	  	  
Overall,	   the	   six	  versions	  of	   the	  new	  tool	   showed	  similar	  performance	   in	  
validation	   analyses.	   These	   results	   are	   in	   line	   with	   what	   found	   during	   the	  
preliminary	   validation	   phase	   of	   our	   work	   (see	   Second	   part	   of	   the	   present	  
dissertation).	  	  
We	  are	  now	  planning	  to	  carry	  on	  a	  large-­‐scale	  prospective	  validation	  of	  the	  
new	  tool,	  thanks	  to	  the	   involvement	  of	  a	   large	  number	  of	   international	  centres	  
that	   are	   part	   of	   the	   main	   paediatric	   rheumatology	   networks	   worldwide.	   Each	  
center	  will	  be	  asked	  to	  enroll	  all	  consecutive	  and	  unselected	  patients	  meeting	  the	  
Bohan	  and	  Peter	   criteria	   for	   JDM,	   seen	  consecutively	  within	   the	   first	  6	  months	  
after	  the	  study	  start.	  Informed	  consent	  will	  be	  obtained	  from	  all	  study	  patients.	  
Each	  patient	  enrolled	   should	  undergo	  a	   retrospective	  evaluation,	  based	  on	   the	  
review	  of	   the	   clinical	   chart,	   and	   two	   cross-­‐sectional	   assessments	   at	   least	   three	  
months	  apart.	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The	  aim	  of	  such	  a	  prospective	  collection	  of	  consecutive	  patients	  is	  mainly	  
to	  select	  the	  final	  version	  of	  the	  JDMAI	  among	  the	  six	  preliminary	  ones	  proposed,	  
based	  on	  the	  observed	  metrologic	  performance	  of	  these	  various	  versions	  in	  a	  large	  
cohort	   of	   patients	   seen	   in	   standard	   clinical	   practice.	   The	   JDMAI	   is	   the	   first	  
composite	   disease	   activity	   score	   for	   JDM,	   and	   combines	   information	   from	   3	  
physician-­‐centered	   measures	   and	   1	   parent/patient-­‐centered	   measure	   into	   a	  
continuous	  measure	  of	   inflammation.	   The	   score	  of	   the	   JDMAI	   results	   from	   the	  
arithmetic	   sum	   of	   the	   scores	   of	   each	   individual	   component,	   which	   makes	   its	  
calculation	  simple	  and	  quick.	  The	  JDMAI	  proved	  good	  measurement	  properties	  in	  
preliminary	   validation	   analysis	   and	   is	   a	   valid	   instrument	   for	   the	   assessment	   of	  
disease	  activity	  in	  JDM.	  Therefore,	  it	  is	  potentially	  applicable	  in	  standard	  clinical	  
care,	  observational	  studies	  and	  clinical	  trials.	  	  
The	   overall	   prognosis	   of	   JDM	   has	   improved	   significantly	   over	   the	   last	  
decades,	  but	  the	  long-­‐term	  outcomes	  differs	  substantially	  from	  patient	  to	  patient,	  
suggestive	  of	  distinct	  clinical	  phenotypes	  with	  variable	   responses	   to	   treatment.	  
Early	  and	  aggressive	  therapy	  may	  prevent	  or	  stabilize	  organ	  damage	  and	  disease	  
complications	  like	  calcinosis.	  High	  doses	  of	  corticosteroids	  remain	  the	  cornerstone	  
of	  therapy	  along	  with	  other	  immunosuppressant	  therapies	  depending	  on	  disease	  
severity	  and	   response.	  The	  general	   treatment	  goals	  now	   include	  elimination	  of	  
active	  disease	  and	  normalization	  of	  physical	   function,	  so	  as	   to	  preserve	  normal	  
growth	  and	  development,	  and	  to	  prevent	  long-­‐term	  damage	  and	  deformities	  [9,	  
51].	  	  
These	  advances	  have	  increased	  the	  potential	  for	  achievement	  of	  disease	  
remission	  or,	  at	  least,	  low	  levels	  of	  disease	  activity,	  and	  have	  consequently	  moved	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the	   therapeutic	  aims	   increasingly	   toward	  attainment	  of	   inactive	  disease	   status,	  
similarly	  to	  what	  already	  seen	  in	  other	  pediatric	  rheumatologic	  diseases,	  such	  as	  	  
JIA	  [52].	  For	  reliable	  documentation	  of	  the	  advances	  in	  therapeutic	  efficacy,	  there	  
is	   a	   need	   for	   validated	   and	   clinically	   useful	   criteria	   that	   describe	   precisely	   the	  
clinical	  states	  of	  remission	  or	  near-­‐remission.	  	  
One	  approach	   to	  defining	   remission	   is	   based	  on	   the	  use	  of	   core	   sets	  of	  
multiple	   criteria,	   such	   as	   those	   included	   in	   PRINTO	   preliminary	   definition	   of	  
remission,	   according	   to	   which	   a	   patient	   is	   defined	   as	   clinically	   inactive	   on/off	  
therapy	   if	   at	   least	   three	  of	   four	   of	   the	   following	  measures	  meet	   the	   proposed	  
inactivity	  cut-­‐offs:	  1)	  CPK	  ≤	  150	  IU,	  2)	  CMAS	  ≥	  48,	  3)	  MMT8	  ≥	  78,	  and	  4)	  Physician’s	  
Global	   VAS	   ≤0.2	   [53].	   However,	   achievement	   of	   a	   complete	   absence	   of	   any	  
measurable	  sign	  of	  disease	  activity	  is	  infrequent	  in	  the	  clinical	  practice,	  particularly	  
among	  patients	  with	  polycyclic	  or	  continuous	  disease	  course.	  This	  highlights	  the	  
need	   for	   establishing	   a	   well-­‐defined	   state	   of	   minimal	   disease	   activity	   as	   an	  
intermediate	  state	  between	  high	  disease	  activity	  and	  remission,	  though	  very	  close	  
to	   remission.	  The	  criteria	   for	   inactive	  disease	   [53]	  are	  based	  only	  on	  physician-­‐
reported	  outcomes	  and	  a	  muscle	  enzyme	  level,	  whereas	  parent	  proxy-­‐reported	  
and	   child	   self-­‐reported	  outcomes	  are	  neglected.	  Hence,	  definition	  of	   remission	  
may	   not	   adequately	   reflect	   the	   parent’s	   and	   child’s	   perception	   of	   the	   disease	  
status.	   The	   need	   to	   know	   whether	   a	   therapeutic	   intervention	   leads	   to	   an	  
acceptable	  state	  according	  to	  the	  parent	  or	  the	  child	  has	   led	  us	  to	  propose	  the	  
concept	  of	  parent/child	  acceptable	  symptom	  state	  in	  JIA	  [43];	  this	  concept	  can	  be	  
similarly	  applied	  in	  JDM.	  	  
An	  alternative	  approach	  to	  the	  measurement	  of	  disease	  activity	  is	  based	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on	  composite	  disease	  activity	  scores.	  To	  aid	  in	  the	  interpretation	  of	  scores	  in	  the	  
JDMAI,	  cutoff	  values	  are	  needed	  for	  identifying	  the	  main	  disease	  activity	  states	  in	  
JDM	   (i.e.	   clinically	   inactive	   disease,	  minimal	   disease	   activity,	  moderate	   disease	  
activity,	   and	   high	   disease	   activity),	   similarly	   to	   what	   already	   done	   to	   aid	   in	  
interpretation	  of	  scores	  of	  the	  Juvenile	  Arthritis	  Disease	  Activity	  Score	  (JADAS),	  a	  
similar	  composite	  disease	  activity	   tool	   recently	  developed	  and	  validated	   for	   JIA	  
[20].	  These	  definitions,	  at	  present	  not	  available,	  may	  provide	  simple	  and	  intuitive	  
reference	  values	  that	  can	  be	  used	  to	  monitor	  the	  disease	  course	  over	  time	  in	  an	  
individual	   patient	   or	   to	   compare	   disease	   status	   across	   individual	   patients	   or	  
patient	  groups.	  Furthermore,	  they	  may	  support	  decisions	  about	  enrollment	  into	  
clinical	   trials	   as	  well	   as	   requirements	   for	   changes	   in	   therapies	   and	   for	   defining	  
therapeutic	  goals.	  	  
However,	   we	   do	   not	   believe	   the	   cutoffs	   should	   be	   used	   to	   “diagnose”	  
remission.	   Rather,	   they	   represent	   an	   additional	   clinical	   tool	   that,	   if	   applied	  
regularly	   in	   daily	   practice,	   may	   allow	   tighter	   therapeutic	   control	   of	   disease,	  
support	   the	  optimization	  of	   treatment	  on	   an	   individual	   patient	   basis,	   and	  help	  
prevent	   the	   development	   of	   damage	   and	   physical	   disability.	   Studies	   in	   adult	  
Rheumatoid	  Arthritis	  have	  shown	  that	  patient	  outcomes	  are	  improved	  if	  low	  levels	  
of	  disease	  activity	  are	  aimed	  for	  by	  frequent	  adjustments	  of	  therapy	  according	  to	  
quantitative	   indices	   [54-­‐56].	   These	   observations	   have	   led	   to	   suggest	   that	   the	  
strategy	   of	   tight	   control,	   aiming	   for	   remission,	   is	   more	   important	   than	   the	  
medication	  [57].	  Similar	  considerations	  may	  be	  valid	  for	  JDM	  as	  well,	  as	  it	  is	  widely	  
recognized	  that	  persistently	  active	  disease	  plays	  a	  major	  role	  in	  causing	  disease-­‐
related	  damage	  and	  physical	  functional	  disability.	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The	  incorporation	  of	  the	  treat-­‐to-­‐target	  strategy	  in	  clinical	  trials	  requires	  
the	  availability	  of	  validated	  and	  clinically	  useful	  criteria	  that	  describes	  accurately	  
the	  clinical	  states	  of	  remission	  or	  near-­‐remission.	  The	  JDMAI	  may	  be	  suitable	  to	  
implement	  a	  treat-­‐to-­‐target	  approach	  in	  JDM	  aimed	  to	  achieve	  and	  maintain	  tight	  
disease	  control,	  with	  treatment	  escalation	  if	  a	  target	  JDMAI	  score	  is	  not	  reached,	  
and	  may	  serve	  as	  an	  effective	  primary	  outcome	  measure	  in	  a	  therapeutic	  trial	  in	  
JDM.	  	  	  
The	   search	   for	   biomarkers	   in	   pediatric	   rheumatic	   diseases	   is	   attracting	  
increased	   interest.	  As	   regards	   JDM,	  some	  evidence	  suggests	   that	   this	  condition	  
may	  be	  classified	  according	   to	   the	  presence	  of	  myositis-­‐specific	  autoantibodies	  
and	   myositis-­‐associated	   autoantibodies;	   these	   autoantibodies	   define	   fairly	  
homogeneous	   groups	   of	   patients	   with	   similar	   clinical	   features,	   responses	   to	  
therapy,	  and	  prognoses.	  To	  be	  noticed,	  no	  reliable	  biomarker	  of	  disease	  activity	  is	  
currently	   available	   for	   JDM.	   In	   the	   coming	   years,	   the	   discovery	   of	   additional	  
biomarkers	  and	  their	   incorporation	  in	  daily	  practice	  to	  predict	  disease	  outcome	  
and	  response	  to	  therapy	  in	  individual	  patients	  could	  facilitate	  the	  adoption	  of	  a	  
stratified	  approach	   to	  diagnosis	  and	  management,	  and	  ultimately	   lead	   to	  more	  
rational	   and	   effective	   clinical	   care.	   Furthermore,	   use	   of	   biomarkers	   may	  
potentially	  help	  to	  avoid	  invasive	  procedures,	  such	  as	  muscle	  biopsy	  in	  JDM	  [58].	  
While	  waiting	  for	  these	  advances	  to	  get	  real,	  the	  usefulness	  of	  a	  composite	  disease	  
activity	  score	  like	  JDMAI,	  that	  is	  quickly	  and	  easily	  calculated,	  becomes	  even	  more	  
evident,	   as	   we	   lack	   the	   availability	   of	   any	   surrogate	   biomarker	   of	   the	   level	   of	  
disease	  activity	  in	  JDM.	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APPENDIX	  	  
	  
Appendix	   to	   the	   Second	   Part:	   PRELIMINARY	   VALIDATION	   OF	   THE	  
JUVENILE	  DERMATOMYOSITIS	  ACTIVITY	  INDEX	  (JDMAI)	  
	  
Table	  A1.	  Assessment	  of	   the	  ability	  of	  different	   JDMAI	  versions	   to	  discriminate	  
patients	  judged	  as	  being	  in	  the	  states	  of	   inactive	  disease,	  continuous	  activity	  or	  
flare	  by	  the	  physician	  in	  all	  visits	  in	  the	  Routine	  dataset	  in	  which	  this	  evaluation	  
was	  available.	  	  
	  
	   	   N	   Mean	  (SD)	   Median	  [IQR]	   Min	  -­‐	  Max	   P	  
JDMAI	  1	   	  Inactive	   180	   1.8	  (2.3)	   1	  [0	  -­‐	  2.5]	   0	  -­‐	  12	   <	  0.0001	  
	   	  Continuous	  activity/flare	   183	   8.8	  (7.2)	   6.5	  [3.5	  -­‐	  11]	   0.5	  -­‐	  31.5	   	  
JDMAI	  2	   	  Inactive	   166	   2.6	  (2.8)	   1.5	  [0.5	  -­‐	  4]	   0	  -­‐	  12.5	   <	  0.0001	  
	   	  Continuous	  activity/flare	   166	   10.7	  (6.8)	   8.5	  [6	  -­‐	  13]	   0.5	  -­‐	  32	   	  
JDMAI	  3	   	  Inactive	   185	   1.7	  (2.3)	   1	  [0	  -­‐	  2.5]	   0	  -­‐	  12	   <	  0.0001	  
	   	  Continuous	  activity/flare	   187	   8.7	  (7.1)	   6.5	  [3.5	  -­‐	  10.5]	   0	  -­‐	  31	   	  
JDMAI	  4	   	  Inactive	   171	   2.5	  (2.9)	   1.5	  [0	  -­‐	  4]	   0	  -­‐	  13.5	   <	  0.0001	  
	   	  Continuous	  activity/flare	   170	   10.6	  (6.8)	   9	  [6	  -­‐	  13]	   0	  -­‐	  31.5	   	  
JDMAI	  5	   	  Inactive	   152	   1.8	  (2.3)	   1	  [0	  -­‐	  2.5]	   0	  -­‐	  12	   <	  0.0001	  
	   	  Continuous	  activity/flare	   148	   8.8	  (7)	   6.5	  [4.5	  -­‐	  11]	   0.5	  -­‐	  32.5	   	  
JDMAI	  6	   	  Inactive	   146	   2.6	  (2.9)	   1.5	  [0	  -­‐	  4]	   0	  -­‐	  12	   <	  0.0001	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  Continuous	  activity/flare	   139	   10.5	  (6.7)	   8.5	  [6	  -­‐	  12.5]	   0.5	  -­‐	  33	   	  
IQR:	  Interquartile	  Range;	  P:	  Non	  parametric	  test:	  Mann-­‐Whitney	  U	  test.	  
	  
Table	  A2.	  Assessment	  of	   the	  ability	  of	  different	   JDMAI	  versions	   to	  discriminate	  
patients	  judged	  as	  being	  in	  the	  states	  of	  inactive	  disease,	  low,	  moderate	  or	  high	  
disease	  activity	  by	  the	  physician	  in	  all	  visits	   in	  the	  Routine	  dataset	  in	  which	  this	  
evaluation	  was	  available.	  	  
	  
	   	   N	   Mean	  (SD)	   Median	  [IQR]	   Min	  -­‐	  Max	   p	  
JDMAI	  1	   	  Inactive	   180	   1.8	  (2.3)	   1	  [0	  -­‐	  2.5]	   0	  -­‐	  12	   <	  0.0001	  
	   	  Low	  disease	  activity	   116	   5.3	  (3.2)	   4.5	  [3	  -­‐	  7]	   1	  -­‐	  18	   	  
	   	  Moderate	  disease	  activity	   50	   12.4	  (6.3)	   11	  [7.5	  -­‐	  16]	   2.5	  -­‐	  29	   	  
	   	  High	  disease	  activity	   14	   24.8	  (6)	   26	  [23.5	  -­‐	  29]	   8.5	  -­‐	  31.5	   	  
JDMAI	  2	   	  Inactive	   166	   2.6	  (2.8)	   1.5	  [0.5	  -­‐	  4]	   0	  -­‐	  12.5	   <	  0.0001	  
	   	  Low	  disease	  activity	   104	   7.5	  (3.6)	   7.3	  [5.5	  -­‐	  9]	   1	  -­‐	  19	   	  
	   	  Moderate	  disease	  activity	   48	   14.3	  (6.3)	   13.5	  [8.8	  -­‐	  18]	   6	  -­‐	  29	   	  
	   	  High	  disease	  activity	   11	   25.9	  (4.4)	   27.5	  [22.5	  -­‐	  28.5]	   18	  -­‐	  32	   	  
JDMAI	  3	   	  Inactive	   185	   1.7	  (2.3)	   1	  [0	  -­‐	  2.5]	   0	  -­‐	  12	   <	  0.0001	  
	   	  Low	  disease	  activity	   118	   5.2	  (3.2)	   4.5	  [3	  -­‐	  7]	   0	  -­‐	  18.5	   	  
	   	  Moderate	  disease	  activity	   52	   12.3	  (6.2)	   11	  [7.3	  -­‐	  16]	   2.5	  -­‐	  29	   	  
	   	  High	  disease	  activity	   14	   24.8	  (6.1)	   25.8	  [23.5	  -­‐	  30]	   8.5	  -­‐	  31	   	  
JDMAI	  4	   	  Inactive	   171	   2.5	  (2.9)	   1.5	  [0	  -­‐	  4]	   0	  -­‐	  13.5	   <	  0.0001	  
	   	  Low	  disease	  activity	   106	   7.4	  (3.6)	   7	  [5.5	  -­‐	  9]	   0	  -­‐	  19	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  Moderate	  disease	  activity	   50	   14.1	  (6.1)	   13.3	  [9.5	  -­‐	  18]	   6	  -­‐	  29	   	  
	   	  High	  disease	  activity	   11	   26	  (4.5)	   27.5	  [23.5	  -­‐	  29]	   17	  -­‐	  31.5	   	  
JDMAI	  5	   	  Inactive	   152	   1.8	  (2.3)	   1	  [0	  -­‐	  2.5]	   0	  -­‐	  12	   <	  0.0001	  
	   	  Low	  disease	  activity	   95	   5.6	  (3.3)	   5	  [3.5	  -­‐	  7]	   1	  -­‐	  19	   	  
	   	  Moderate	  disease	  activity	   41	   12.6	  (6.4)	   11	  [7.5	  -­‐	  16.5]	   4	  -­‐	  30	   	  
	   	  High	  disease	  activity	   9	   26	  (4.8)	   26.5	  [22.5	  -­‐	  29]	   19	  -­‐	  32.5	   	  
JDMAI	  6	   	  Inactive	   146	   2.6	  (2.9)	   1.5	  [0	  -­‐	  4]	   0	  -­‐	  12	   <	  0.0001	  
	   	  Low	  disease	  activity	   88	   7.7	  (3.6)	   7.5	  [5.5	  -­‐	  9]	   1	  -­‐	  20	   	  
	   	  Moderate	  disease	  activity	   40	   14.1	  (6.6)	   12	  [9	  -­‐	  18.8]	   5.5	  -­‐	  30	   	  
	   	  High	  disease	  activity	   8	   25.3	  (5.5)	   24.5	  [20.8	  -­‐	  30.3]	   18	  -­‐	  33	   	  
IQR	  =	  Interquartile	  Range;	  P:	  Non	  parametric	  analysis	  of	  variance:	  Kruskal-­‐Wallis	  test.	  
	  
Table	  A3.	  Assessment	  of	   the	  ability	  of	  different	   JDMAI	  versions	   to	  discriminate	  
between	  patients	  whose	  parents	  were	  satisfied	  or	  not	  satisfied	  with	  the	  course	  of	  
their	  child’s	  illness	  in	  all	  visits	  in	  the	  Routine	  dataset	  in	  which	  this	  evaluation	  was	  
available.	  
	  
	   	   N	   Mean	  (SD)	   Median	  [IQR]	   Min	  -­‐	  Max	   p	  
JDMAI	  1	   	  Satisfied	   270	   3.3	  (4)	   2	  [1	  -­‐	  4.5]	   0	  -­‐	  26	   <	  0.0001	  
	   	  Not	  satisfied	   78	   13.1	  (8.4)	   10.3	  [6.5	  -­‐	  18]	   1.5	  -­‐	  31.5	   	  
JDMAI	  2	   	  Satisfied	   256	   4.5	  (4.5)	   3.3	  [1	  -­‐	  7]	   0	  -­‐	  25	   <	  0.0001	  
	   	  Not	  satisfied	   71	   14.9	  (8)	   12.5	  [8.5	  -­‐	  21.5]	   1.5	  -­‐	  32	   	  
JDMAI	  3	   	  Satisfied	   275	   3.3	  (4.1)	   2	  [0.5	  -­‐	  4.5]	   0	  -­‐	  27	   <	  0.0001	  
	   51	  
	   	  Not	  satisfied	   81	   12.8	  (8.4)	   10	  [6.5	  -­‐	  18]	   0.5	  -­‐	  31	   	  
JDMAI	  4	   	  Satisfied	   261	   4.4	  (4.6)	   3.5	  [1	  -­‐	  7]	   0	  -­‐	  26	   <	  0.0001	  
	   	  Not	  satisfied	   74	   14.6	  (8)	   12	  [8.5	  -­‐	  19]	   0.5	  -­‐	  31.5	   	  
JDMAI	  5	   	  Satisfied	   224	   3.5	  (4.2)	   2	  [0.5	  -­‐	  5]	   0	  -­‐	  24	   <	  0.0001	  
	   	  Not	  satisfied	   67	   12.5	  (8.1)	   10	  [6.5	  -­‐	  17.5]	   1.5	  -­‐	  32.5	   	  
JDMAI	  6	   	  Satisfied	   218	   4.6	  (4.7)	   3.5	  [1	  -­‐	  7]	   0	  -­‐	  23	   <	  0.0001	  
	   	  Not	  satisfied	   64	   14	  (7.9)	   11.8	  [8	  -­‐	  19.3]	   1.5	  -­‐	  33	   	  
IQR	  =	  Interquartile	  Range;	  P:	  Non	  parametric	  test:	  Mann-­‐Whitney	  U	  test.	  
	  
Figure	  A1.	  Graphic	  representation	  of	  the	  ability	  of	  JDMAI3,	  JDMAI4,	  JDMAI5,	  and	  
JDMAI6	  to	  discriminate	  patients	  judged	  as	  being	  in	  the	  states	  of	  inactive	  disease	  
or	  low,	  moderate	  or	  high	  disease	  activity	  by	  the	  physician	  in	  the	  Routine	  sample.	  	  	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  






























  1st - 3rd quartile  





























  1st - 3rd quartile  






























  1st - 3rd quartile  





























  1st - 3rd quartile  
  Min - max
	   52	  
	  	  
Figure	  A2.	  Graphic	  representation	  of	  the	  ability	  of	  JDMAI	  3,	  JDMAI	  4,	  JDMAI	  5,	  and	  
JDMAI6	   to	   discriminate	   between	   patients	  whose	   parents	  were	   satisfied	   or	   not	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Appendix	  to	  the	  Third	  Part:	  PRELIMINARY	  PROSPECTIVE	  VALIDATION	  
OF	  THE	  JUVENILE	  DERMATOMYOSITIS	  ACTIVITY	  INDEX	  (JDMAI)	  
	  
Figure	  A3.	  Capacity	   of	   the	   JDMAI2	   to	   discriminate	   between	   activity	   states	   and	  




Figure	  A4.	  Capacity	   of	   the	   JDMAI3	   to	   discriminate	   between	   activity	   states	   and	  
parent	  satisfaction/non	  satisfaction	  in	  the	  Prospective	  sample.	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Figure	  A5.	  Capacity	   of	   the	   JDMAI4	   to	   discriminate	   between	   activity	   states	   and	  
parent	  satisfaction/non	  satisfaction	  in	  the	  Prospective	  sample.	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Figure	  A6.	  Capacity	   of	   the	   JDMAI5	   to	   discriminate	   between	   activity	   states	   and	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Figure	  A7.	  Capacity	  of	  the	  JDMAI6	  to	  discriminate	  between	  activity	  states	  and	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